[
  {
    "text": "--- Page 1 ---\nTextbook of\nDiabetes\nEDITED BY\nRICHARD I.G. HOLT\nMA, MB BChir, PhD, FRCP, FHEA\nProfessor in Diabetes & Endocrinology\nDevelopmental Origins of Health and Disease Division\nUniversity of Southampton School of Medicine\nSouthampton, UK\nCLIVE S. COCKRAM\nMB BS, BSc, MD (Lond), FRCP, FRACP, FHKAM (Med)\nEmeritus Professor of Medicine\nChinese University of Hong Kong\nHong Kong SAR\nPeople’s Republic of China\nALLAN FLYVBJERG\nMD, DMSc\nProfessor of Clinical Endocrinology and\nChair, Department of Endocrinology and Internal Medicine\nThe Medical Research Laboratories\nAarhus University Hospital – Aarhus University\nAarhus, Denmark\nBARRY J. GOLDSTEIN\nMD, PhD, FACP, FACE\nTherapeutic Area Head, Diabetes and Obesity\nVice President, Clinical Research, Metabolism\nMerck Research Laboratories\nRahway, NJ, USA\nFOURTH EDITION\nA John Wiley & Sons, Ltd., Publication",
    "chunk_id": 0,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 860
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 1
    }
  },
  {
    "text": "--- Page 2 ---",
    "chunk_id": 1,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 14
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 2
    }
  },
  {
    "text": "--- Page 3 ---\nTextbook of Diabetes\nCOMPANION WEBSITE\nPurchasing this book entitles you to access to the companion website:\ntextbookofdiabetes.com\nThe website includes:\n(cid:129) Interactive Multiple-Choice Questions for each chapter\n(cid:129) Reference lists with external links\n(cid:129) Figures from the book for downloading\n(cid:129) All chapters online\nHow to access the site:\n(cid:129) Scratch off the label below to see your unique PIN number\n(cid:129) Go to the website textbookofdiabetes.com and follow the registration instructions\nSCRATCH CODE HERE\nPlease note that the book cannot be returned once the label is scratched off, and the unique (personal)\nPIN cannot be shared. The site is for individual use by purchasers only and cannot be networked.",
    "chunk_id": 2,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 760
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 3
    }
  },
  {
    "text": "--- Page 4 ---\nW e dedicate this book to all people living with diabetes and the healthcare\nprofessionals who look after them. We would also like to dedicate this book to our\nfamilies without whose support and encouragement the book would never have\nbeen fi nished.",
    "chunk_id": 3,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 265
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 4
    }
  },
  {
    "text": "--- Page 5 ---\nTextbook of\nDiabetes\nEDITED BY\nRICHARD I.G. HOLT\nMA, MB BChir, PhD, FRCP, FHEA\nProfessor in Diabetes & Endocrinology\nDevelopmental Origins of Health and Disease Division\nUniversity of Southampton School of Medicine\nSouthampton, UK\nCLIVE S. COCKRAM\nMB BS, BSc, MD (Lond), FRCP, FRACP, FHKAM (Med)\nEmeritus Professor of Medicine\nChinese University of Hong Kong\nHong Kong SAR\nPeople’s Republic of China\nALLAN FLYVBJERG\nMD, DMSc\nProfessor of Clinical Endocrinology and\nChair, Department of Endocrinology and Internal Medicine\nThe Medical Research Laboratories\nAarhus University Hospital – Aarhus University\nAarhus, Denmark\nBARRY J. GOLDSTEIN\nMD, PhD, FACP, FACE\nTherapeutic Area Head, Diabetes and Obesity\nVice President, Clinical Research, Metabolism\nMerck Research Laboratories\nRahway, NJ, USA\nFOURTH EDITION\nA John Wiley & Sons, Ltd., Publication",
    "chunk_id": 4,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 860
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 5
    }
  },
  {
    "text": "--- Page 6 ---\nThis edition fi rst published 2010. © 1991, 1997, 2003, 2010 by Blackwell Publishing Ltd\nBlackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program\nhas been merged with Wiley’s global Scientifi c, Technical and Medical business to form Wiley-Blackwell. Registered offi ce: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ,\nUK\nEditorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK\n111 River Street, Hoboken, NJ 07030-5774, USA\nThe Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK\nFor details of our global editorial offi ces, for customer services and for information about how to apply for\npermission to reuse the copyright material in this book please see our website at www.wiley.com/\nwiley-blackwell. The right of the author to be identifi ed as the author of this work has been asserted in accordance with the\nCopyright, Designs and Patents Act 1988. All rights reserved.",
    "chunk_id": 5,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 990
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 6
    }
  },
  {
    "text": "No part of this publication may be reproduced, stored in a retrieval system, or transmitted,\nin any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as\npermitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not\nbe available in electronic books. Designations used by companies to distinguish their products are often claimed as trademarks. All brand\nnames and product names used in this book are trade names, service marks, trademarks or registered\ntrademarks of their respective owners. The publisher is not associated with any product or vendor mentioned\nin this book. This publication is designed to provide accurate and authoritative information in regard to the\nsubject matter covered. It is sold on the understanding that the publisher is not engaged in rendering\nprofessional services.",
    "chunk_id": 6,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 992
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 6
    }
  },
  {
    "text": "If professional advice or other expert assistance is required, the services of a competent\nprofessional should be sought. The contents of this work are intended to further general scientifi c research, understanding, and discussion\nonly and are not intended and should not be relied upon as recommending or promoting a specifi c method,\ndiagnosis, or treatment by physicians for any particular patient. The publisher and the author make no\nrepresentations or warranties with respect to the accuracy or completeness of the contents of this work and\nspecifi cally disclaim all warranties, including without limitation any implied warranties of fi tness for a\nparticular purpose.",
    "chunk_id": 7,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 676
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 6
    }
  },
  {
    "text": "In view of ongoing research, equipment modifi cations, changes in governmental\nregulations, and the constant fl ow of information relating to the use of medicines, equipment, and devices, the\nreader is urged to review and evaluate the information provided in the package insert or instructions for each\nmedicine, equipment, or device for, among other things, any changes in the instructions or indication of\nusage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of\nfurther information does not mean that the author or the publisher endorses the information the organization\nor Website may provide or recommendations it may make. Further, readers should be aware that Internet\nWebsites listed in this work may have changed or disappeared between when this work was written and when\nit is read.",
    "chunk_id": 8,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 953
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 6
    }
  },
  {
    "text": "No warranty may be created or extended by any promotional statements for this work. Neither the\npublisher nor the author shall be liable for any damages arising herefrom. ISBN: 9781405191814\nA catalogue record for this book is available from the British Library. Library of Congress Cataloging-in-Publication Data\nTextbook of diabetes. – 4th ed. / edited by Richard I.G. Holt ... [et al.]. p. ; cm. Includes bibliographical references and index. ISBN 978-1-4051-9181-4 (hardback : alk. paper)\n1. Diabetes. I. Holt, Richard I.G. [DNLM: 1. Diabetes Mellitus. WK 810 T355 2010]\nRC660.T467 2010\n616.4'62–dc22\n2010013907\nSet in 9.25/12 pt Minion by Toppan Best-set Premedia Limited\nPrinted in Singapore\n1 2010",
    "chunk_id": 9,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 704
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 6
    }
  },
  {
    "text": "--- Page 7 ---\nContents\nList of Contributors, ix Part 3 Pathogenesis of Diabetes\nPreface to the Fourth Edition, xiii\n9 Type 1 Diabetes, 141\nForeword, xv Autoimmune Type 1 Diabetes, 141\nAhmed J. Delli, Helena Elding Larsson, Sten-A. Ivarsson\nList of Abbreviations, xvi\n& Åke Lernmark\nOther Disorders with Type 1 Phenotype, 152\nPart 1 Diabetes in its Historical and Alice P.S. Kong & Juliana C.N. Chan\nSocial Context\n10 Abnormalities of Insulin Secretion and β-Cell Defects in\nType 2 Diabetes, 160\n1 The History of Diabetes Mellitus, 3\nMazen Alsahli & John E. Gerich\nRobert B. Tattersall\n11 Insulin Resistance in Type 2 Diabetes, 174\n2 The Classifi cation and Diagnosis of Diabetes, 24\nHannele Yki-Järvinen\nK. George M.M. Alberti\n12 The Genetics of Type 2 Diabetes: From Candidate Gene\n3 Epidemiology of Type 1 Diabetes, 31\nBiology to Genome-Wide Studies, 191\nLars C.",
    "chunk_id": 10,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 865
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 7
    }
  },
  {
    "text": "Stene, Valma Harjutsalo, Elena Moltchanova\nMartine Vaxillaire & Philippe Froguel\n& Jaakko Tuomilehto\n13 Metabolic Disturbances in Diabetes, 215\n4 Epidemiology of Type 2 Diabetes, 45\nAdrian Vella & Robert A. Rizza\nRonald C.W. Ma & Peter C.Y. Tong\n14 Obesity and Diabetes, 227\n5 The Global Burden of Diabetes, 69\nHans Hauner\nMohammed K. Ali, Mary Beth Weber & K.M. Venkat\nNarayan\nPart 4 Other Types of Diabetes\nPart 2 Normal Physiology\n15 Monogenic Causes of Diabetes, 245\nAngus Jones & Andrew T. Hattersley\n6 Islet Function and Insulin Secretion, 87\nPeter M. Jones & Shanta J. Persaud 16 Drug-Induced Diabetes, 265\nNeil J.L. Gittoes, John Ayuk & Robin E. Ferner\n7 Insulin Action, 104\nXuxia Wu & W. Timothy Garvey 17 Endocrine Disorders that Cause Diabetes, 279\nNeil A. Hanley\n8 Control of Weight: How Do We Get Fat? 126\nGeorge A. Bray 18 Pancreatic Diseases and Diabetes, 298\nRanjit Unnikrishnan & Viswanathan Mohan\nv",
    "chunk_id": 11,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 916
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 7
    }
  },
  {
    "text": "--- Page 8 ---\nContents\nPart 5 Managing the Patient with Part 7 Microvascular Complications\nDiabetes in Diabetes\n19 Clinical Presentations of Diabetes, 313 35 Pathogenesis of Microvascular Complications, 555\nEe Lin Lim & Roy Taylor Ferdinando Giacco & Michael Brownlee\n20 The Aims of Diabetes Care, 323 36 Diabetic Retinopathy, 575\nRichard I.G. Holt & Barry J. Goldstein Peter H. Scanlon\n21 Educating the Patient with Diabetes, 334 37 Diabetic Nephropathy, 599\nCarolé Mensing & Barbara Eichorst Sally M. Marshall & Allan Flyvbjerg\n22 Lifestyle Issues: Diet, 346 38 Diabetic Peripheral Neuropathy, 615\nMonika Toeller Dan Ziegler\n23 Lifestyle Issues: Exercise, 358\nJane E. Yardley, Angela Alberga, Glen P. Kenny\n& Ronald J. Sigal Part 8 Macrovascular Complications\nin Diabetes\n24 Social Aspects of Diabetes, 380\nBrian M. Frier & Mark W.J. Strachan\n39 The Pathogenesis of Macrovascular Complications\n25 Monitoring Diabetes, 399 Including Atherosclerosis in Diabetes, 637\nAndrew J.",
    "chunk_id": 12,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 977
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 8
    }
  },
  {
    "text": "Farmer Riccardo Candido, Mark E. Cooper & Karin A.M. Jandeleit-Dahm\n26 Drug Therapy: Special Considerations\nin Diabetes, 410 40 Cardiovascular Risk Factors, 657\nBernard M.Y. Cheung & Robin E. Ferner Hypertension, 657\nPeter M. Nilsson\nDyslipidemia: Diabetes Lipid Therapies, 672\nPart 6 Treatment of Diabetes\nAdie Viljoen & Anthony S. Wierzbicki\n27 Insulin and Insulin Treatment, 427 41 Congestive Heart Failure, 684\nStephen Gough & Parth Narendran Inga S. Thrainsdottir & Lars Rydén\n28 New Technologies for Insulin Administration and Glucose 42 Cerebrovascular Disease, 698\nMonitoring, 440 Colum F. Amory & Jesse Weinberger\nHoward Wolpert & Judy Shih\n43 Peripheral Vascular Disease, 710\n29 Oral Antidiabetic Agents, 452 Henrik H. Sillesen\nClifford J. Bailey & Andrew J.",
    "chunk_id": 13,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 768
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 8
    }
  },
  {
    "text": "Krentz\n30 Non-Insulin Parenteral Therapies, 478\nPart 9 Other Complications of Diabetes\nJens Juul Holst, Sten Madsbad & Ole Schmitz\n31 How to Use Type 2 Diabetes Treatments in Clinical 44 Foot Problems in Patients with Diabetes, 727\nPractice: Combination Therapies, 494 Andrew J.M. Boulton\nJoseph A. Aloi & Anthony L. McCall\n45 Sexual Function in Men and Woman with Diabetes, 743\n32 In-Hospital Treatment and Surgery in Patients with David Price\nDiabetes, 514\n46 Gastrointestinal Manifestations of Diabetes, 760\nMaggie Sinclair Hammersley & June James\nAdil E. Bharucha & Michael Camilleri\n33 Hypoglycemia in Diabetes, 528\n47 The Skin in Diabetes, 774\nPhilip E. Cryer\nGraham R. Sharpe & Paul D. Yesudian\n34 Acute Metabolic Complications of Diabetes: Diabetic\n48 Bone and Rheumatic Disorders in Diabetes, 789\nKetoacidosis and Hyperosmolar Hyperglycemia, 546\nAndrew Grey & Nicola Dalbeth\nTroels Krarup Hansen & Niels Møller\nvi",
    "chunk_id": 14,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 922
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 8
    }
  },
  {
    "text": "--- Page 9 ---\nContents\n49 Psychologic Factors and Diabetes, 807 Part 12 Future Directions\nChristopher M. Ryan\n59 Future Drug Treatment for Type 1 Diabetes, 1001\n50 Diabetes and Infections, 835\nHelena Elding Larsson, Ahmed J. Delli, Sten-A. Ivarsson\nClive S. Cockram & Nelson Lee\n& Åke Lernmark\n60 Future Drug Treatments for Type 2 Diabetes, 1017\nPart 10 Diabetes in Special Groups Clifford J. Bailey\n61 Other Future Directions, 1045\n51 Diabetes in Childhood, 859\nStem Cell Therapy in Diabetes, 1045\nChristine Chan & Marian Rewers\nShuibing Chen, Jayaraj Rajagopal, Qiao Zhou &\n52 Diabetes in Adolescence and Transitional Care, 875 Douglas A. Melton\nDebbie Kralik & Maria Kambourakis\nIslet Transplantation, 1050\n53 Diabetes in Pregnancy, 888 Angela Koh, Peter Senior & A.M. James Shapiro\nAnne Dornhorst & Anita Banerjee\nGene Therapy, 1064\n54 Diabetes in Old Age, 922 Andreea R. Barbu & Nils Welsh\nAlan J.",
    "chunk_id": 15,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 903
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 9
    }
  },
  {
    "text": "Sinclair\n62 Future Models of Diabetes Care, 1070\n55 Psychiatric Disorders and Diabetes, 940 Robert A. Gabbay & Alan M. Adelman\nRobert C. Peveler & Richard I.G. Holt\nIndex, 1081\nPart 11 Delivery and Organization\nof Diabetes Care\n56 The Role of Community and Specialist Services, 959\nJane Overland, Margaret McGill & Dennis K. Yue\n57 The Role of the Multidisciplinary Team, 969\nWing-Yee So & Juliana C.N. Chan\n58 Models of Diabetes Care Across Different\nResource Settings, 984\nA companion website for this book is available at:\nNaomi S. Levitt, Bob Mash, Nigel Unwin, Jean Claude\ntextbookofdiabetes.com\nMbanya, Jae-Hyoung Cho & Kun-Ho Yoon\nvii",
    "chunk_id": 16,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 641
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 9
    }
  },
  {
    "text": "--- Page 10 ---",
    "chunk_id": 17,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 15
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 10
    }
  },
  {
    "text": "--- Page 11 ---\nList of Contributors\nAlan M. Adelman MS, MD Clifford J. Bailey PhD, FRCP(Edin), Michael Camilleri MD\nProfessor of Family and Community Medicine, Vice FRCPath Atherton and Winifred W. Bean Professor, Professor\nChair for Academic Affairs and Research, Penn State Professor in Clinical Science and Head of Diabetes of Medicine and Physiology, College of Medicine,\nMilton S.",
    "chunk_id": 18,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 386
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 11
    }
  },
  {
    "text": "Hershey Medical Center, Penn State Research, School of Life and Health Sciences, Aston Mayo Clinic and Clinical Enteric Neuroscience\nCollege of Medicine, Hershey, PA, USA University, Birmingham, UK Translational and Epidemiological Research\nProgram, Division of Gastroenterology and\nAngela Alberga MSc Anita Banerjee BSc, MBBS, MRCP Hepatology, Mayo Clinic, Rochester, MN, USA\nF aculty of Health Sciences, University of Ottawa and Obstetric Physician, Diabetes and Endocrinology,\nOttawa Hospital Research Institute, Ottawa, Princess Royal University Hospital, London, Riccardo Candido MD, PhD\nOntario, Canada England UK Diabetic Centre, Trieste, Italy\nK. George M.M. Alberti DPhil, FRCP Andreea R. Barbu PhD Christine M.",
    "chunk_id": 19,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 720
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 11
    }
  },
  {
    "text": "Chan MD\nSenior Research Fellow, Imperial College, London; Department of Medical Cell Biology and Barbara Davis Center for Childhood Diabetes,\nEmeritus Professor of Medicine, University of Department of Medical Sciences, Uppsala University of Colorado Denver, School of Medicine,\nNewcastle, Newcastle, UK University, Uppsala, Sweden Aurora, CO, USA\nMohammed K. Ali MBChB, MSc Adil E. Bharucha MD Juliana C.N. Chan MBChB MD FRCP\nAssistant Professor, Hubert Department of Global Professor of Medicine, Division of Gastroenterology Professor of Medicine and Therapeutics, Director,\nHealth, Rollins School of Public Health, Global and Hepatology, Clinical Enteric Neuroscience Hong Kong Institute of Diabetes and Obesity, The\nDiabetes Research Center, Emory University, Translational and Epidemiological Research Chinese University of Hong Kong, The Prince of\nAtlanta, GA, USA Program, Mayo Clinic, Rochester, MN, USA Wales Hospital, Hong Kong SAR, China\nJoseph A. Aloi MD Andrew J.M.",
    "chunk_id": 20,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 979
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 11
    }
  },
  {
    "text": "Boulton MD, DSc (Hon), Shuibing Chen PhD\nAssociate Professor of Internal Medicine, The\nFRCP\nPostdoctoral Fellow, Department of Stem Cell and\nStrelitz Diabetes Center for Endocrine and Regenerative Biology, Harvard University,\nProfessor of Medicine, University of Manchester\nMetabolic Disorders, Eastern Virginia Medical Cambridge, MA, USA\nand Manchester Royal Infi rmary, Manchester, UK;\nSchool , Norfolk, VA, USA\nMiller School of Medicine, University of Miami,\nMiami, FL, USA Bernard M.Y. Cheung MD, PhD\nMazen Alsahli MD Chair of Clinical Pharmacology and Therapeutics,\nProfessor of Medicine, University of Rochester George A. Bray MD, MACP Department of Clinical Pharmacology, University of\nSchool of Medicine, Rochester, NY, USA Birmingham, Birmingham, UK\nBoyd Professor, Pennington Biomedical Research\nCenter, Louisiana State University, Baton Rouge,\nColum F.",
    "chunk_id": 21,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 863
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 11
    }
  },
  {
    "text": "Amory MD, MPH LA, USA Jae - Hyoung Cho MD\nMount Sinai School of Medicine, New York, NY, Assistant Professor, Department of Endocrinology,\nUSA Michael Brownlee MD Seoul St. Mary ’ s Hospital, College of Medicine, The\nCatholic University of Korea, Seoul, Korea\nAnita and Jack Saltz Professor of Diabetes Research,\nJohn Ayuk MD Albert Einstein College of Medicine, New York, NY,\nCentre for Endocrinology, Diabetes and USA Mark E. Cooper MD, PhD\nMetabolism, University of Birmingham and Queen Director, Danielle Alberti JDRF Centre for Diabetes\nElizabeth Hospital Birmingham, Birmingham, UK Complications, Head, Vascular Division – Baker IDI\nHeart Research Institute, Melbourne, Australia\nix",
    "chunk_id": 22,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 687
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 11
    }
  },
  {
    "text": "--- Page 12 ---\nList of Contributors\nPhilip E. Cryer MD Ferdinando Giacco PhD Sten – A. Ivarsson MD, PhD\nI rene E. and Michael M. Karl Professor of Postdoctoral Fellow, Diabetes Research and Training Clinical Research Center (CRC), Lund University\nEndocrinology and Metabolism in Medicine, Center, Departments of Medicine and and Department of Clinical Sciences/Paediatric\nWashington University School of Medicine, St. Endocrinology, Albert Einstein College of Medicine, Endocrinology, University Hospital MAS, Malm ö ,\nLouis, MO, USA New York, NY, USA Sweden\nNicola Dalbeth MD, FRACP Neil J.L. Gittoes MD June James MSc, BA (Hons) Dip Nursing,\nDepartment of Medicine, University of Auckland, Senior Lecturer in Medicine, Centre for NP RGN\nAuckland, New Zealand Endocrinology, Diabetes and Metabolism, Consultant Nurse in Diabetes, University Hospitals\nUniversity of Birmingham and Queen Elizabeth of Leicester, Leicester, UK\nAhmed J.",
    "chunk_id": 23,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 934
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 12
    }
  },
  {
    "text": "Delli MD, MPH Hospital Birmingham, Birmingham, UK\nClinical Research Center (CRC), Lund University, Karin A.M.",
    "chunk_id": 24,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 109
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 12
    }
  },
  {
    "text": "Jandeleit- Dahm MD, PhD,\nDepartment of Clinical Sciences/Diabetes and Celiac Steve Gough\nFRACP\nDisease, University Hospital MAS, Malmö , Sweden Professor of Diabetes, Oxford Centre for Diabetes\nB aker IDI Heart and Diabetes Institute, Co- h ead,\nEndocrinology and Metabolism, University of\nDiabetes Division; Professor of Medicine (Adjunct),\nAnne Dornhorst BSc, DM, FRCP, FRCPath Oxford; Consultant Physician, Churchill Hospital, Monash University, Melbourne, Australia\nOxford, UK\nC onsultant Physician, Honorary Senior Lecturer,\nDepartment of Medicine, Imperial College Peter Jones PhD\nHealthcare NHS Trust, Hammersmith Hospital, Andrew Grey MD\nProfessor of Endocrine Biology, King ’ s College\nLondon, UK Department of Medicine, University of Auckland,\nLondon, London, UK\nAuckland, New Zealand\nBarbara Eichorst MS,RD,CDE Angus Jones MBBS, MRCP\nHealthy Interactions Global Conversation Map ™ Maggie Sinclair Hammersley MB,\nDiabetes and Vascular Medicine, Peninsula Medical\nFacilitator, Chicago, IL, USA FRCP School, Exeter, UK\nConsultant Physician and Senior Lecturer, Nuffi eld\nAndrew J.",
    "chunk_id": 25,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 1088
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 12
    }
  },
  {
    "text": "Farmer DM, FRCGP Department of Medicine, University of Oxford, Maria Kambourakis BSc(Hons)\nU niversity Lecturer, Department of Primary Health Oxford, UK\nResearch Offi cer/Type 1 Diabetes Program Offi cer,\nCare, University of Oxford, Oxford, UK\nType 1 Diabetes Program, Diabetes Australia,\nNeil A. Hanley MBChB, PhD Victoria, Australia\nRobin E. Ferner MSc, MD, FRCP Professor of Medicine, Endocrinology and Diabetes\nProfessor, West Midlands Centre for Adverse Drug Group, University of Manchester, Manchester, UK Glen P. Kenny MD\nReactions, City Hospital, Birmingham, UK\nOttawa Hospital Research Institute and Laboratory\nTroels Krarup Hansen MD, PhD of Human Bioenergetics and Environmental\nBrian M.",
    "chunk_id": 26,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 698
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 12
    }
  },
  {
    "text": "Frier BSc(Hons), MD, FRCPE, A ssociate Professor, Department of Endocrinology Physiology, School of Human Kinetics, Faculty of\nFRCPG and Internal Medicine, Aarhus University Hospital, Health Sciences, University of Ottawa, Ottawa,\nProfessor, Department of Diabetes, Royal Infi rmary Aarhus, Denmark Ontario, Canada\nof Edinburgh, Edinburgh, UK\nValma Harjutsalo PhD Angela Koh MBBS (Singapore), MRCP (UK)\nPhilippe Froguel MD, PhD Folkh ä lsan Institute of Genetics, Folkh ä lsan Assistant Professor, Department of Medicine\nInstitut de Biologie de Lille, Institut Pasteur de Lille, Research Center, Biomedicum Helsinki; Diabetes (Endocrinology), Attending Physician, Clinical Islet\nLille, France; Section of Genomic Medicine, Prevention Unit, National Institute of Health and Transplant Program, University of Alberta,\nImperial College London, London, UK Welfare, Helsinki, Finland; Division of Nephrology, Edmonton, Canada\nDepartment of Medicine, Helsinki University\nCentral Hospital, Helsinki, Finland\nRobert A.",
    "chunk_id": 27,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 1010
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 12
    }
  },
  {
    "text": "Gabbay MD, PhD Alice P.S. Kong MBChB, MRCP (UK),\nDirector, Penn State Institute for Diabetes and FRCP (Glasg)\nAndrew T. Hattersley MD\nObesity; Professor of Medicine and Molecular A ssociate Professor, Department of Medicine and\nDiabetes and Vascular Medicine, Peninsula Medical\nMedicine, Penn State College of Medicine; Director, Therapeutics, The Chinese University of Hong\nSchool, Exeter, UK\nDiabetes Program, Penn State Milton S. Hershey Kong, Hong Kong SAR, China\nMedical Center, Hershey, PA , USA\nHans Hauner MD Debbie Kralik PhD, RN\nW.",
    "chunk_id": 28,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 541
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 12
    }
  },
  {
    "text": "Timothy Garvey MD Director, Else Kr ö ner - Fresenius - Center for General Manager, Research and Strategy, Royal\nNutritional Medicine, Klinikum rechts der Isar,\nButterworth Professor and Chair, Department of District Nursing Service, South Australia; Associate\nTechnical University of Munich, Munich, Germany\nNutrition Sciences; Director, UAB Diabetes Professor, University of South Australia and\nResearch and Training Center, University of University of Adelaide, Glenside, Australia\nAlabama at Birmingham; Birmingham Veterans Jens Juul Holst MD, DMSc\nAffairs Medical Center, Birmingham, AL, USA Professor of Medical Physiology, Department of Andrew J. Krentz MD, FRCP\nBiomedical Sciences, The Panum Institute,\nFormerly Southampton University Hospitals NHS\nJohn E. Gerich MD University of Copenhagen, Denmark Trust, Southampton, UK\nProfessor of Medicine, University of Rochester\nSchool of Medicine, Rochester, NY, USA\nx",
    "chunk_id": 29,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 920
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 12
    }
  },
  {
    "text": "--- Page 13 ---\nList of Contributors\nHelena Elding Larsson MD, PhD Margaret McGill RN, MSc(med) Shanta J. Persaud PhD\nClinical Research Center (CRC), Lund University; Diabetes Centre, Royal Prince Alfred Hospital, Professor of Diabetes and Endocrinology, King ’ s\nDepartment of Clinical Sciences/Paediatric Camperdown, Sydney, New South Wales, Australia College London, London, UK\nEndocrinology, University Hospital MAS, Malm ö ,\nSweden Douglas A. Melton Robert C.",
    "chunk_id": 30,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 464
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "Peveler MA, DPhil, BM, BCh,\nThomas Dudley Cabot Professor in the Natural FRCPsych\nNelson Lee MD,FRCP(Edin) Sciences, Department of Stem Cell and Regenerative Clinical Neurosciences Division, School of\nAssociate Professor, Head, Division of Infectious Biology; Harvard Stem Cell Institute; Investigator, Medicine, University of Southampton and Royal\nDiseases, Department of Medicine and Therapeutics, Howard Hughes Medical Institute, Harvard South Hants Hospital, Southampton, UK\nFaculty of Medicine, The Chinese University of University, Cambridge, MA, USA\nHong Kong, Hong Kong SAR, China\nDavid Price MD, FRCP\nCarol é R.",
    "chunk_id": 31,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 620
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "Mensing RN, MA, CDE Department of Diabetes and Endocrinology,\nÅ ke Lernmark PhD Joslin Diabetes Center, Boston, MA, USA Morriston Hospital, Swansea, UK\nProfessor of Experimental Diabetes, Lund\nUniversity/CRC, Department of Clinical Sciences, Viswanathan Mohan MD, FRCP(UK), Jayaraj Rajagopal\nUniversity Hospital MAS, Malm ö , Sweden\nFRCP(Glasg), PhD, DSc, FNASc C enter for Regenerative Medicine, Massachusetts\nChairman and Chief Diabetologist, Dr. Mohan ’ s General Hospital; Principal Investigator, Harvard\nNaomi S.",
    "chunk_id": 32,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 517
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "Levitt MBChB, MD, FCP(SA) Diabetes Specialities Centre, WHO Collaborating Stem Cell Institute, Boston, MA, USA\nProfessor and Head of Division of Diabetic Centre for Non Communicable Diseases Prevention\nMedicine and Endocrinology, Department of and Control, IDF Centre of Education; President Marian Rewers MD, PhD\nMedicine, University of Cape Town and Groote and Chief of Diabetes Research, Madras Diabetes\nProfessor, Pediatrics and Preventive Medicine;\nSchuur Hospital, Cape Town, South Africa Research Foundation, ICMR Advanced Centre for\nClinical Director, Barbara Davis Center for\nGenomics of Diabetes, Gopalapuram, Chennai,\nChildhood Diabetes, University of Colorado Denver,\nEe Lin Lim MRCP India School of Medicine, Aurora, CO, USA\nDiabetes Research Group, Institute of Cellular\nMedicine, University of Newcastle, Newcastle upon Niels M ø ller MD, DMSc Robert A.",
    "chunk_id": 33,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 868
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "Rizza MD\nTyne, UK Professor, Department of Endocrinology and\nProfessor of Medicine, Division of Endocrinology,\nInternal Medicine, The Medical Research\nDiabetes, Metabolism and Nutrition, Mayo Clinic,\nRonald C.W. Ma MB BChir, MRCP Laboratories, Arhus University Hospital, Arhus, Rochester, MN, USA\nAssociate Professor, Division of Endocrinology and Denmark\nDiabetes, Department of Medicine and\nChristopher M. Ryan PhD\nTherapeutics, The Chinese University of Hong Elena Moltchanova PhD\nProfessor of Psychiatry, University of Pittsburgh\nKong, Prince Of Wales Hospital, Hong Kong SAR, Diabetes Unit, Department of Health Promotion\nSchool of Medicine, Pittsburgh, Pennsylvania, USA\nChina and Chronic Disease Prevention, National Institute\nfor Health and Welfare, Helsinki, Finland\nSten Madsbad MD, DMSc Lars Rydé n MD, FRCP, FESC, FACC, FAHA\nProfessor Emeritus, Cardiology Unit, Department of\nProfessor of Diabetology, Department of K. M.",
    "chunk_id": 34,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 933
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "Venkat Narayan MD, MSc, MBA,\nMedicine, Karolinska Institute, Stockholm, Sweden\nEndocrinology, Hvidovre Hospital, Hvidovre,\nFRCP\nDenmark\nRuth and O.C. Hubert Professor of Global Health,\nPeter H. Scanlon MD, MRCOphth, DCH,\nProfessor of Epidemiology and Medicine, Rollins\nSally M. Marshall MD School of Public Health, Emory University, Atlanta, FRCP\nP rofessor of Diabetes, Diabetes Research Group, GA, USA Consultant Ophthalmologist, Gloucestershire and\nInstitute of Cellular Medicine, Newcastle University, Oxford Eye Units; Lecturer, Harris Manchester\nNewcastle upon Tyne, UK Parth Narendran College, University of Oxford, Oxford, UK\nInstitute of Biomedical Research, The Medical\nBob Mash MBChB, MRCGP, PhD School, University of Birmingham, Birmingham, Ole Schmitz MD, DMSc\nP rofessor, Division of Family Medicine and Primary UK Professor of Clinical Pharmacology, Department of\nCare, Stellenbosch University, Tygerberg, South Clinical Pharmacology, Aarhus University Hospital,\nAfrica Peter M.",
    "chunk_id": 35,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 993
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "Nilsson MD Denmark\nProfessor of Clinical Cardiovascular Research,\nJean - Claude Mbanya MD, PhD, FRCP Department of Clinical Sciences, Lund University, Peter A. Senior BMedSci, MBBS, PhD,\nP rofessor of Medicine and Endocrinology, Faculty University Hospital, Malmö , Sweden MRCP(UK)\nof Medicine and Biomedical Sciences, University of Clinical Islet Transplant Program, University of\nYaounde I, Yaounde, Cameroon Jane Overland MPH, PhD Alberta, Edmonton, Alberta, Canada\nNurse Practitioner, Diabetes Centre, Royal Prince\nAnthony L. McCall MD, PhD Alfred Hospital, Campderdown, New South Wales, A.M. James Shapiro MD PhD DSc (Hon)\nJames M.",
    "chunk_id": 36,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 636
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "Moss Professor of Diabetes in Internal Australia; Clinical Associate Professor, The Faculty FRCS(Eng) FRCSC MSM\nMedicine, Diabetes and Hormone Center of of Nursing and Midwifery, The University of P rofessor of Surgery, Director, Clinical Islet\nExcellence, University of Virginia School of Sydney, Sydney, Australia Transplant Program, AHFMR Scholar, University of\nMedicine, Charlottesville, VA, USA Alberta, Edmonton, Canada\nxi",
    "chunk_id": 37,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 428
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 13
    }
  },
  {
    "text": "--- Page 14 ---\nList of Contributors\nGraham R. Sharpe MBChB, BA, PhD, FRCP Peter C.Y. Tong MBBS, PhD, BPharm, FRCP Anthony S. Wierzbicki DM, DPhil,\nC onsultant Dermatologist, Department of Professor, Division of Endocrinology and Diabetes, FRCPath, FAHA\nDermatology, Broadgreen Hospital, Liverpool, UK Department of Medicine and Therapeutics, The Consultant Metabolic Physician and Chemical\nChinese University of Hong Kong and Prince Of Pathologist, Guy ’ s and St Thomas Hospitals,\nJudy Shih MD, PhD Wales Hospital, Hong Kong SAR, China London, UK\nJoslin Diabetes Center, Boston, MA, USA\nJaakko Tuomilehto MD, MA, PhD Howard Wolpert MD\nRonald J.",
    "chunk_id": 38,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 646
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 14
    }
  },
  {
    "text": "Sigal MD, MPH, FRCPC Hjelt Institute, University of Helsinki and Diabetes Joslin Diabetes Center, Boston, MA, USA\nPrevention Unit, Department of Health Promotion,\nProfessor of Medicine, Cardiac Sciences, and\nNational Institute for Health and Welfare, Helsinki,\nCommunity Health Sciences, Faculties of Medicine Xuxia Wu MD, PhD\nFinland, and South Ostrobothnia Central Hospital,\nand Kinesiology, The University of Calgary, Canada Department of Nutrition Sciences, University of\nSein ä joki, Finland\nAlabama at Birmingham, Birmingham, AL, USA\nHenrik H. Sillesen MD, DMSc\nRanjit Unnikrishnan MD\nHead, Department of Vascular Surgery, Jane E. Yardley MSc\nDirector and Consultant Diabetologist, Dr.",
    "chunk_id": 39,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 691
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 14
    }
  },
  {
    "text": "Mohan ’ s\nRigshospitalet, University of Copenhagen, F aculty of Health Sciences, University of Ottawa and\nDiabetes Specialities Centre, WHO Collaborating\nCopenhagen, Denmark Ottawa Hospital Research Institute, Ottawa,\nCentre for Non Communicable Diseases Prevention\nOntario, Canada\nand Control and IDF Centre of Education, Madras\nAlan J. Sinclair MSc, MD, FRCP Diabetes Research Foundation, ICMR Advanced\nDeputy Dean and Professor of Medicine, Centre for Genomics of Diabetes, Chennai, India Paul D.",
    "chunk_id": 40,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 499
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 14
    }
  },
  {
    "text": "Yesudian MB, MD, MRCP\nBedfordshire and Hertfordshire Postgraduate C onsultant Dermatologist, Department of\nMedical School; Geriatric and Diabetes Research Nigel Unwin BA, MSc, DM, FRCP, FFPH Dermatology, University of Liverpool and\nCentre, University of Bedfordshire, Luton, UK Broadgreen Hospital, Liverpool, UK\nProfessor of Public Health and Epidemiology,\nFaculty of Medicine, University of the West Indies,\nWing - Yee So MBChB, MD, FRCP Barbados Hannele Yki- J är vinen MD, FRCP\nAssociate Consultant, Prince of Wales Hospital, Professor of Medicine, Department of Medicine,\nHong Kong SAR, China Martine Vaxillaire PharmD, PhD Division of Diabetes, University of Helsinki,\nHelsinki, Finland\nResearch Director at Pasteur Institute, CNRS 8090\nLars C.",
    "chunk_id": 41,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 750
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 14
    }
  },
  {
    "text": "Stene PhD and Pasteur Institute, Lille, France\nDivision of Epidemiology, Norwegian Institute of Kun - Ho Yoon MD, PhD\nPublic Health, Oslo, Norway; Oslo Diabetes Adrian Vella MD, FRCP(Edin) Professor, Department of Endocrinology and\nResearch Centre, Oslo University Hospital, Oslo, Metabolism, Seoul St. Mary ’ s Hospital, College of\nA ssociate Professor of Medicine, Division of\nNorway Medicine, The Catholic University of Korea, Seoul,\nEndocrinology, Diabetes, Metabolism and Nutrition,\nKorea\nMayo Clinic, Rochester, MN, USA\nMark W. J. Strachan MD, FRCP (Edin)\nC onsultant in Diabetes and Endocrinology, Adie Viljoen MBChB, MMed, FCPath (SA), Dennis K. Yue MBBS, FRACP, PhD\nMetabolic Unit, Western General Hospital, Diabetes Centre, Royal Prince Alfred Hospital;\nEdinburgh, UK FRCPath, MBA University of Sydney, Sydney, New South Wales,\nConsultant Chemical Pathologist, Department of\nAustralia\nChemical Pathology, Lister Hospital, Stevenage, UK\nRobert B.",
    "chunk_id": 42,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 955
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 14
    }
  },
  {
    "text": "Tattersall MB, ChB, MD, FRCP\nEmeritus Professor of Clinical Diabetes, University Qiao Zhou\nof Nottingham, Nottinghamshire, UK Mary Beth Weber MPH Assistant Professor, Department of Stem Cell and\nNutrition and Health Sciences Program, Graduate\nRegenerative Biology, Principle Investigator,\nDivision of Biological and Biomedical Sciences,\nRoy Taylor MD, FRCP Harvard Stem Cell Institute, Havard University,\nGlobal Diabetes Research Center, Emory University,\nP rofessor of Medicine and Metabolism, and Cambridge, MA, USA\nAtlanta, GA, USA\nDirector, Newcastle Magnetic Resonance Centre,\nNewcastle University, Newcastle upon Tyne, UK Dan Ziegler MD, FRCPE\nJesse Weinberger MD\nProfessor of Internal Medicine, Institute for Clinical\nDepartment of Neurology, Mount Sinai School of\nInga S.",
    "chunk_id": 43,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 779
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 14
    }
  },
  {
    "text": "Thrainsdottir MD, PhD Diabetology, German Diabetes Center at the\nMedicine, New York, NY, USA\nDepartment of Cardiology, Landspitali University Heinrich Heine University, Leibniz Center for\nHospital, Reykjavik, Iceland Diabetes Research; Department of Metabolic\nNils Welsh MD, PhD Diseases, University Hospital, D ü sseldorf, Germany\nP rofessor in Molecular Infl ammation Research,\nMonika Toeller MD\nDepartment of Medical Cell Biology, Uppsala\nGerman Diabetes Center, Heinrich Heine University\nUniversity, Uppsala, Sweden\nD ü sseldorf and Leibniz Center for Diabetes\nResearch, D ü sseldorf, Germany\nxii",
    "chunk_id": 44,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 600
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 14
    }
  },
  {
    "text": "--- Page 15 ---\nPreface to the Fourth Edition\nT he management of diabetes is a major health challenge, and its Alongside the developments in the pathophysiology of\nprevalence is increasing at an alarming rate, especially in the diabetes have come major advances in the treatment of diabetes. developing world. According to the International Diabetes Some of these therapeutic innovations have been withdrawn,\nFederation, diabetes currently affects more than 285 million such as inhaled insulin, but many have been adopted in\npeople worldwide, a fi gure that is expected to rise to 435 million clinical practice. The development of new oral agents to treat type\nby 2030. During the writing of this book over the last 18 months, 2 diabetes has diversifi ed choices for clinicians and people\napproximately 15 million people will have developed diabetes. with diabetes.",
    "chunk_id": 45,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 865
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 15
    }
  },
  {
    "text": "Drugs affecting glucagon - like peptide 1 (GLP - 1)\nAlthough treatments continue to improve, many people die as a and the incretin axis that were mentioned briefl y as future treat-\nresult of their diabetes. Between 6 – 16% of all deaths are attribut- ments in the last edition are now fi rmly established as effective\nable to diabetes and around 900 will have died in the 2 hours treatments of type 2 diabetes. Many studies have highlighted\ntaken to write this preface. Diabetes accounts for about 6% of the advantages and disadvantages of the newer agents making the\ntotal global mortality, on a par with that seen in HIV/AIDS. Many choice of treatment more complicated than ever. Beyond the\nof these deaths will result from cardiovascular disease which gluco - centric view of diabetes, major cardiovascular trials con-\noccurs at least twice as often in diabetes as in people without tinue to show the benefi ts of statin therapy in people with\ndiabetes.",
    "chunk_id": 46,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 957
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 15
    }
  },
  {
    "text": "Diabetes continues to cause suffering through its com- diabetes. plications. It is the commonest cause of kidney failure in devel- The publication of this new edition is timely given the rapid\noped countries where it is also the leading cause of blindness in advances in knowledge. This edition has a new editorial team\nadults of working age. Diabetes is also a major cause of non - drawn from the UK, Europe, USA and Asia to refl ect the global\ntraumatic lower limb amputation. As well as the personal cost, nature of the diabetes epidemic. The new team has experienced\ndiabetes places a huge burden on health economies. In 2010, it is a big learning curve and we are profoundly grateful that we could\nestimated that worldwide, at least US$ 376 billion will be used to stand on the shoulders of John Pickup and Gareth Williams, the\ntreat and prevent diabetes and its complications. Never have the editors of the previous three editions.",
    "chunk_id": 47,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 937
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 15
    }
  },
  {
    "text": "The new book has retained\nchallenges in providing diabetes healthcare been larger. many of the excellent author team brought together by John and\nDuring the eight years since the publication of the previous Gareth and the structure is similar to the previous editions. edition of this textbook, there have been great strides in the man- Nevertheless like any new teams we have tried to improve the\nagement and understanding of diabetes. International collabora- book while keeping the sound ideas from the previous book. The\ntions using large and varied cohorts with increasingly sophisticated book has been shortened into one volume to make it easier to\ntechnologies have allowed a greater appreciation of the genetic use. We have emphasized the clinical aspects of diabetes to a\nfactors that predispose to diabetes.",
    "chunk_id": 48,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 817
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 15
    }
  },
  {
    "text": "Our molecular understanding greater extent than previous editions and refl ecting the diverse\nof insulin resistance and the regulation of insulin secretion has locations of the editors, the chapter authors are also dispersed\nincreased as has our appreciation of the mechanisms underlying throughout the globe making this a truly international textbook\ncomplications. which crosses continents and highlights both developed and\nThe diagnostic criteria look set to be changed again and may developing health systems. incorporate hemoglobin A1c (HbA ) while the units of the latter As editors we are only too aware of the work that many people\n1c\nhave also recently changed to refl ect the development of more have contributed to the book, without which our endeavors\nreliable and traceable assays. As HbA remains the currency of would have been much harder, if not impossible.",
    "chunk_id": 49,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 873
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 15
    }
  },
  {
    "text": "The chapter\n1c\neveryday diabetes practice, these changes will provide major edu- authors are at the top of our list for our gratitude. Their willing-\ncational challenges for patients and professionals alike. ness to devote their time and effort into compiling scholarly and\nxiii",
    "chunk_id": 50,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 278
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 15
    }
  },
  {
    "text": "--- Page 16 ---\nPreface to the Fourth Edition\nrelevant chapters, while tolerating nagging e - mails from us, has Our thanks also go to Rob Blundell (Production Editor) and\nbeen humbling. In an age where book writing often comes fourth Helen Harvey (Project Manager) in the production team. behind grant and paper writing and clinical work, we are grateful We hope you enjoy reading the book and fi nd it useful whether\nfor the way that the authors met the deadlines set by us. We this is helping people with diabetes or teaching physicians and\nare also grateful for the immense help we have received from other health professionals how best to manage this disease and\nour publisher, Wiley - Blackwell. Our Commissioning Editor its complications. Oliver Walter, who took over from Alison Brown shortly into the\nbook ’ s development, has provided encouragement, support and Richard I.G. Holt\nguidance as has Jennifer Seward, the Development Editor. Often Clive S.",
    "chunk_id": 51,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 961
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 16
    }
  },
  {
    "text": "Cockram\njust at the time when things appeared to be insurmountable, Allan Flyvbjerg\nOliver or Jennifer took steps to get the project moving again. Barry J. Goldstein\nxiv",
    "chunk_id": 52,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 169
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 16
    }
  },
  {
    "text": "--- Page 17 ---\nForeword\nThe face of diabetes is forever changing. Scientific knowledge able routinely a century ago. The world pandemic of diabetes is\nincreases exponentially and our understanding slowly improves described with few populations spared and then each type of\nalthough there are still massive gaps in many fundamental aspects diabetes is described together with what is known of their patho-\nof the diabetes story, such as the mechanisms underlying the physiology. Particularly valuable are the essays on non - classical\ndevelopment of type 2 diabetes. Trying to keep up with all the type 1 and type 2 diabetes. advances is an ever increasing burden, but with a large array of The management and treatment of diabetes from education\nmeans to achieve this.",
    "chunk_id": 53,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 769
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 17
    }
  },
  {
    "text": "Many people use the web, both specific through lifestyle modifi cation and the use of oral agents and\nwebsites and more general search engines, but there are still a insulin is dealt with exhaustively with useful chapters on the oft\nlarge number of people who prefer the printed word and the col- ignored psychological and social aspects of the disorder. Different\nlection together of an accessible compendium where you can models of care are also well discussed. Complications are dealt\nexpect to obtain answers to your questions. This volume provides with comprehensively and again the book is of particular value\nexactly that; namely a series of up - to - date, well referenced, in going beyond the classical complications and dealing with a\nlearned articles covering the manifold manifestations of diabetes range of less well defi ned problems found in people with diabetes. together with the basic underlying science.",
    "chunk_id": 54,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 922
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 17
    }
  },
  {
    "text": "It is truly comprehen- The book fi nishes with crystal ball gazing: a look at future drugs\nsive and I would challenge any reader to find missing aspects for both type 1 and type 2 diabetes, as well as the potential for\nof the pathophysiology, treatment and care of people with stem cell therapy, islet cell transplantation and gene therapy, all\ndiabetes. of which are thought provoking and informative. T he book begins with a fascinating historical essay which Overall I feel that this volume fulfi ls a major need for anyone\nshould be read by anybody who picks up the book. It reminds us with an interest in diabetes; it should be available in every setting\nthat much valuable information is forgotten and many lessons where people with diabetes receive their care and will serve as an\ncan be learned by going back to pre - internet days! The possibility excellent vade mecum.",
    "chunk_id": 55,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 878
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 17
    }
  },
  {
    "text": "of using HbA for the diagnosis of diabetes is discussed refl ecting\n1c\na potentially seismic shift in our diagnostic armamentarium that K. George M.M. Alberti\nhas relied on the measurement of glucose since that became avail- I mperial College London\nxv",
    "chunk_id": 56,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 252
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 17
    }
  },
  {
    "text": "--- Page 18 ---\nList of Abbreviations\nAA arachidonic acid BUN blood urea nitrogen\nAAA abdominal aortic aneurysm CABG coronary artery bypass grafting\nAACE American Association of Clinical CAD coronary artery disease\nEndocrinologists CaMK calcium/calmodulin - dependent kinase\nAADE American Association of Diabetes Educators cAMP cyclic adenosine monophosphate\nABI ankle brachial index C A- M RSA c ommunity- a ssociated methicillin- r esistant\nA CA a cetyl co- e nzyme A Staphylococcus aureus\nACC acetyl - CoA carboxylase CAP Cbl associated protein\nACCORD Action to Control Cardiovascular Risk in CAPD continuous ambulatory peritoneal dialysis\nDiabetes CART cocaine and amfetamine - related transcript\nACE American College of Endocrinology CBF cerebral blood fl ow\nACE angiotensin - converting enzyme CBT cognitive – behavioral therapy\nACEi angiotensin - converting enzyme inhibitor CCA calcium - channel antagonist\nACR albumin : creatinine ratio CCK cholecystokinin\nACS acute coronary syndromes CCM Chronic Care Model\nACTH adrenocorticotropic hormone CD celiac disease\nA DA A merican Diabetes Association CDC Centers for Disease Control and Prevention\nADASP autoimmune diabetes in adults with slowly CDFC comprehensive diabetic foot examination\nprogressive β - cell failure CDK cyclin - dependent kinase\nADI acceptable daily intake C EL c arboxyl ester lipase\nAGE advanced glycation end - product CETP cholesterol ester transfer protein\nAGRP agouti - related peptide CFTR cystic fi brosis transmembrane conductance\nALT alanine aminotransferase regulator\nAMI acute myocardial infarction CGM continuous glucose monitoring\nAMPK adenosine 5′ - monophosphate - activated protein cGMP cyclic guanosine monophosphate\nkinase CGMS continuous glucose monitoring systems\nAPC antigen - presenting cell CGRP calcitonin gene - related peptide\nARB angiotensin receptor blocker CHD coronary heart disease\nAST aspartate aminotransferase CHF congestive heart failure\nAT angiotensin CHO Chinese hamster ovary\nATG antithymocyte globulin CI confi dence interval\nBB bio - breeding cIMT carotid intima - media thickness\nBCG bacille Calmette – Gu é rin CKD chronic kidney disease\nBIPSS bilateral inferior petrosal sinus sampling C ML c arboxymethyl lysine\nBMD bone mineral density CN Charcot neuroarthropathy\nBMI body mass index CNV copy number variant\nB NP B - t ype natriuretic peptide CoA coenzyme A\nBP blood pressure COX cyclo - oxygenase\nxxvvii",
    "chunk_id": 57,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 2425
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 18
    }
  },
  {
    "text": "--- Page 19 ---\nList of Abbreviations\ncPLA cytosolic PLA eNOS endothelial nitric oxide synthase\n2 2\nCPT carnitine palmitoyltransferase EPA eicosapentaenoic acid\nCRH corticotropin releasing hormone EPAC exchange protein activated by cyclic AMP\nC RP C - r eactive protein EPC endothelial progenitor cell\nCRS congenital rubella syndrome ER endoplasmic reticulum\nCSII continuous subcutaneous insulin infusion ERCP endoscopic retrograde\nCsA cyclosporine A cholangiopancreatography\nC T c omputed tomography ERK extracellular signal - regulated kinase\nCTGF connective tissue growth factor E RM e zrin- r adixin- m oesin\nCVD cardiovascular disease ESCS electrical spinal cord stimulation\nDAG diacylglycerol ESRD end - stage renal disease\nDASP Diabetes Antibody Standardization Program ESRF end - stage renal failure\nD AWN D iabetes Attitudes, Wishes, and Needs study ET endothelin\nD CCT D iabetes Control and Complications Trial ETDRS Early Treatment Diabetic Retinopathy Study\nDD disc diameter EVAR endovascular aneurysm repair\nDEND developmental delay, epilepsy and neonatal FADH fl avine adenine dinucleotide\n2\ndiabetes FAS fatty acid synthase\nDEXA dual - energy X - ray absorptiometry FCPD fi brocalculous pancreatic diabetes\nDHA docosahexanoic acid FDA Food and Drug Administration\nDHEA dehydroepiandrosterone FDG [ 18 F] - 2 - deoxy - 2 - fl uoro - D - glucose\nDIDMOAD diabetes insipidus, diabetes mellitus, optic FDGF fi broblast - derived growth factor\natrophy and deafness FDR fi rst- d egree relative\nDIGAMI Diabetes mellitus, Insulin Glucose infusion in FFA free fatty acid\nAcute Myocardial Infarction FHWA Federal Highways Administration\nDISH diffuse idiopathic skeletal hyperostosis FPD fi brous proliferation at the disc\nD KA d iabetic ketoacidosis FPE fi brous proliferation elsewhere\nD M d iabetic maculopathy FPG fasting plasma glucose\nDNSG EASD Diabetes and Nutrition Study Group of the FPIR fi rst - phase insulin release\nEuropean Association for the Study of Diabetes FSGS focal segmental glomerular sclerosis\nDPN distal symmetrical sensory or sensorimotor FSH follicle stimulating hormone\npolyneuropathy GABA γ - aminobutyric acid\nDPP Diabetes Prevention Program G AD g lutamine acid decarboxylase\nD PP- 4 d ipeptidyl peptidase 4 GAG glycosaminoglycan\nDQOL Diabetes Quality of Life GAPDH glyceraldehyde - 3 phosphate dehydrogenase\nDR diabetic retinopathy GAS group A streptococcus\nD RS D iabetic Retinopathy Study GDM gestational diabetes mellitus\nDSA digital subtraction angiography GFA glutamine : fructose - 6 - amidotransferase\nDSME diabetes self - management education GFR glomerular fi ltration rate\nDVLA Driver and Vehicle Licensing Agency GH growth hormone\nDVT deep venous thrombosis GHb glycated hemoglobin\nDZ dizygotic GHBP growth hormone - binding protein\neAG estimated average glucose measurement GHD growth hormone defi ciency\nEASD European Association for the Study of Diabetes GHRH growth hormone - releasing hormone\nECG electrocardiography/electrocardiogram GI glycemic index\nED erectile dysfunction GIP glucose - dependent insulinotropic peptide\nEDHF endothelium - derived hyperpolarizing factor GK glucokinase\nEDIC Epidemiology of Diabetes Interventions and GLP glucagon - like peptide\nComplications GLUT glucose transporter\nEDNOS eating disorder not otherwise specifi ed GMP good manufacturing practice\nEEG electroencephalography/electroencephalogram GNSO S - nitrosoglutathione\neGFR estimated glomerular fi ltration rate GP general practitioner\nELISA enzyme - linked immunosorbent assay GRP gastrin - releasing polypeptide\nELISPOT enzyme - linked immunospot assay G stimulatory G - protein\ns\nEMEA European Medicines Agency GSH glutathione\nxvii",
    "chunk_id": 58,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 3676
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 19
    }
  },
  {
    "text": "--- Page 20 ---\nList of Abbreviations\nGSK glycogen synthesis kinase IKK β inhibitor κ - B kinase - β\nGSSG glutathione disulfi de IL interleukin\nGWA genome - wide association INR International Normalized Ratio\nGWL genome - wide familial linkage I OB i nsulin- o n- b oard\nHAAF hypoglycemia - associated autonomic failure IP inositol 1,4,5 - trisphosphate\n3\nHAART highly active antiretroviral therapy IPAN intrinsic primary afferent neuron\nHBO hyperbaric oxygen IPF insulin promoter factor\nH BV h epatitis B virus iPS induced pluripotent cell\nH CV h epatitis C virus IR insulin resistance\nHDL high density lipoprotein IRE inositol - requiring kinase\nHETES hydroxyeicosatetrenoic acids IRE insulin response element\nHFCS high - fructose corn syrup IRMA intraretinal microvascular abnormality\nHGF hepatocyte growth factor IRS insulin receptor substrate\nhGH human recombinant growth hormone ISH International Society of Hypertension\nHH hyperosmolar non - ketotic hyperglycemia IUD intrauterine contraceptive device\nHIC high income country IVGTT intravenous glucose tolerance test\nHIF hypoxia - inducible factor JaK Janus kinase\nHLA human leukocyte antigen JDRF Juvenile Diabetes Research Foundation\nHMa small hemorrhage or microaneurysm JNK c - Jun N - terminal kinase\nHMG high mobility group K m M ichaelis constant\nH NF h epatic nuclear factor KO knockout\nHOMA homeostasis model assessment LADA latent autoimmune diabetes of adults\nHONK hyperosmolar non - ketotic coma LADC latent autoimmune diabetes in children\nHPA hypothalamic - pituitary - adrenal LADY latent autoimmune diabetes in the young\nHPETES hydroperoxyeicosatetrenoic acids LAR leukocyte antigen - related phosphatase\nHR hazard ratio LD linkage disequilibrium\nhrIFN human recombinant interferon LDL low density lipoprotein\nHRT hormone replacement therapy LEAD Liraglutide Effect and Action in Diabetes\nHSL hormone sensitive lipase LGV large goods vehicle\nHSS hyperosmolar hyperglycemic syndrome LH lactic hydrogenase\nIA - 2 insulinoma - associated antigen 2 LI lability index\nI AA i nsulin autoantibody LMIC low and middle income countries\nIAPP islet amyloid polypeptide LOX lipoxygenase\nIBGMS Internet - based glucose monitoring system LPL lipoprotein lipase\nI BMIR i mmediate blood mediated infl ammatory LVH left ventricular hypertrophy\nreaction MACE major adverse cardiovascular event\nICA islet cell antibody MAPK mitogen activated protein kinase\nICAM intercellular adhesion molecule MBL mannose - binding lectin\nICC interstitial cells of Cajal MCH melanin - concentrating hormone\nICCC Innovative Care for Chronic Conditions MCP metacarpophalangeal\nICSA islet surface antibody MCP monocyte chemotactic protein\nIDDM insulin - dependent diabetes mellitus M DI m ultiple daily injection\nIDF International Diabetes Federation MELAS mitochondrial encephalomyopathy, lactic\nIDMPS International Diabetes Management Practice acidosis and stroke -l ike episodes\nStudy MEN multiple endocrine neoplasia\nIENF intra - epidermal nerve fi ber MHC major histocompatibility complex\nIFCC International Federation of Clinical Chemistry M I m yocardial infarction\nIFG impaired fasting glucose MIBI methyloxybutylisonitrile\nIg immunoglobulin MIDD maternal inherited diabetes and deafness\nIGF insulin - like growth factor MMP matrix metalloproteinase\nIGFBP insulin - like growth factor binding protein MnSOD manganese superoxide dismutase\nIGF1R insulin - like growth factor 1 receptor MODY maturity - onset diabetes of the young\nIGT impaired glucose tolerance MR modifi ed release\nIHD ischemic heart disease MRA magnetic resonance angiography\nxviii",
    "chunk_id": 59,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 3589
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 20
    }
  },
  {
    "text": "--- Page 21 ---\nList of Abbreviations\nM RDM m alnutrition- r elated diabetes mellitus OPG osteoprotegerin\nMRI magnetic resonance imaging OR odds ratio\nMRSA methacillin - resistant Staphylococcus aureus ORP oxygen - regulated protein\nMSH melanocyte stimulating hormone PACAP pituitary adenylate cyclase - activating\nMSU monosodium urate polypeptide\nmTOR mammalian target of rapamycin PAD peripheral arterial disease\nMTP microsomal triglyceride transfer protein PAI plasminogen activator inhibitor\nMUFA monounsaturated fatty acid PARP poly(ADP - ribose) polymerase\nMZ monozygotic PCOS polycystic ovary syndrome\nN AA N - a cetyl aspartate PCV passenger - carrying vehicle\nNAC N - acetylcysteine PDE phosphodiesterase\nNADPH nicotinic acid adenine dinucleotide phosphate PDGF platelet - derived growth factor\nNAFLD non - alcoholic fatty liver disease PDK 3 - phosphoinositide - dependent protein kinase\nNAION non - arteritic anterior ischemic optic neuropathy PDR proliferative diabetic retinopathy\nNASH non - alcoholic steatohepatitis PDX pancreatic duodenal homeobox\nNCD non- communicable disease PEG percutaneous endoscopic gastrostomy\nNDDG National Diabetes Data Group PEPCK phosphoenolpyruvate carboxykinase\nNEFA non - esterifi ed fatty acid PET positron emission tomography\nNFG normal fasting glucose P FC p erfl urodecalin\nNF κB n uclear factor κ B PFC prefrontal cortex\nNGF nerve growth factor PGE prostaglandin\nNGT nasogastric tube PH pleckstrin homology\nNGT normal glucose tolerance PHHI persistent hyperinsulinemic hypoglycemia of\nNHANES National Health and Nutrition Examination infancy\nSurvey PI protease inhibitor\nNICE National Institute for Health and Clinical PI phosphoinositide 3′\n3\nExcellence P ID p elvic infl ammatory disease\nNIDDM non - insulin - dependent diabetes mellitus PIP proximal interphalangeal\nNIH National Institutes of Health PIP phosphoinositol 4,5 - bisphosphate\n2\nNIMGU non - insulin - mediated glucose uptake PIP3 phosphatidylinositol 3,4,5 - trisphosphate\nNINDS National Institute of Neurologic Disorders PK protein kinase\nNK natural killer P LC p hospholipase C\nNLD necrobiosis lipoidica diabeticorum PLP periodate - lysine - paraformaldehyde\nNNH number needed to harm P NDM p ermanent neonatal diabetes mellitus\nNNRTI non - nucleoside reverse - transcriptase inhibitor PNMT phenylethanolamine - N - methyltransferase\nNNT number needed to treat POMC pro - opiomelanocortin\nNO nitric oxide POP progesterone - only pill\nN OD n on- o bese diabetic PP pancreatic polypeptide\nNOS nitric oxide synthase PPAR peroxisome proliferator - activated receptor\nNPDR non - proliferative diabetic retinopathy PPG post - prandial plasma glucose\nNPH neutral protamine Hagedorn PPRE peroxisome proliferator response element\nNPWT negative pressure wound therapy PRA panel reactive antibody\nNPY neuropeptide Y PRH preretinal hemorrhage\nNRTI nucleoside reverse - transcriptase inhibitor PTA percutaneous transluminal angioplasty\nNSAID non - steroidal anti - infl ammatory drug PTB phosphotyrosine binding\nNTD neural tube defect PTDM post - transplantation diabetes mellitus\nNVD new vessels on and/or within 1 disc diameter of PTEN phosphatase and tensin homolog\nthe disc PTSD post - traumatic stress disorder\nNVE new vessels elsewhere PTH parathyroid hormone\nNYHA New York Heart Association PTP protein tyrosine phosphatase\nOCP oral contraceptive pill PVD peripheral vascular disease\nOCT optical coherence topography PVN paraventricular nucleus\nOGT O- l inked N - acetylglucosamine transferase QALY quality - adjusted life year\nOGTT oral glucose tolerance test(ing) QST quantitative sensory testing\nxix",
    "chunk_id": 60,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 3615
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 21
    }
  },
  {
    "text": "--- Page 22 ---\nList of Abbreviations\nRAGE receptor for advanced glycation end - product T1DM type 1 diabetes mellitus\nR AI r apid acting analog T2DM type 2 diabetes mellitus\nR ANKL r eceptor activator of nuclear factor κ B ligand TCA tricarboxylic acid\nRAS renin angiotensin system TCA tricyclic antidepressant\nRBP retinol - binding protein TCC total contact cast\nRCAD renal cysts and diabetes syndrome TCC transition case coordinator\nRCW removable cast walker T CF t ranscription factor\nrhIGF recombinant human insulin - like growth factor TCR T - cell receptor\nRMR resting metabolic rate TDI tissue Doppler imaging\nROC receiver operator characteristic TENS transcutaneous electrical nerve stimulation\nROS reactive oxygen species TG triglyceride\nRRT renal replacement therapy TGF transforming growth factor\nRT - CGM real - time continuous glucose monitoring TIA transient ischemic attack\nSADS seasonal affective depressive syndrome T KA t yrosine kinase activity\nSARS severe acute respiratory syndrome TLR toll - like receptor\nSCID severe combined immunodefi ciency TNDM transient neonatal diabetes mellitus\nS D s tandard deviation TNF tumor necrosis factor\nS DF s tromal cell- d erived factor t - PA tissue plasminogen activator\nSDH sorbitol dehydrogenase TRAIL tumor necrosis factor related apoptosis inducing\nSGLT sodium - glucose co - transporter ligand\nSH2 Src homology 2 TSC tuberous sclerosis complex\nSHBG sex hormone - binding globulin TSH thyroid stimulating hormone\nSHIP SH2 - containing inositol phosphatase TZD thiazolidinedione\nSHORT short atature, hyperextensibility of joints, ocular UAE urinary albumin excretion\ndepression, Reiger anamoly, teething delay UCP uncoupling protein\n(syndrome) UDP uridine diphosphate\nSHP2 SH2 - domain - containing tyrosine phosphatase 2 UKPDS UK Prospective Diabetes Study\nSMBG self - monitoring of blood glucose USDA US Department of Agriculture\nSMI serious mental illness UT urotensin\nSMR standardized mortality ratio UTI urinary tract infection\nSNARE soluble N - ethylmaleimide - sensitive factor UW University of Wisconsin solution\nattachment protein receptor VADT Veterans Affairs Diabetes Trial\nSNP single nucleotide polymorphism VB venous beading\nSNRI serotonin noradrenaline reuptake inhibitor VCAM vascular cell adhesion molecule\nSOCS suppressor of cytokine signaling V EGF v ascular endothelial growth factor\nSoHo sorbin homology VH vitreous hemorrhage\nSPECT single photon emission computed tomography VIP vasoactive intestinal polypeptide\ns RAGE s oluble receptor for advanced glycation VLCD very low calorie diet\nend- p roduct VLDL very low density lipoprotein\nSREBP sterol regulatory element - binding protein VNTR variable number tandem repeat\nSSRI selective serotonin reuptake inhibitor V˙ O maximal oxygen consumption\n2max\nSST somatostatin VPT vibration perception threshold\nSSTR somatostatin receptor VSMC vascular smooth muscle cell\nSTAT signal transducer and activator of transcription WHI Women ’ s Health Initiative\nSUR sulfonylurea receptor W HO W orld Health Organization\nt half - life\n1/2\nxx",
    "chunk_id": 61,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 3064
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 22
    }
  },
  {
    "text": "--- Page 23 ---\n1\nDiabetes in its Historical and\nSocial Context",
    "chunk_id": 62,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 63
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 23
    }
  },
  {
    "text": "--- Page 24 ---",
    "chunk_id": 63,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 15
    },
    "document_metadata": {
      "part": "",
      "part_title": "",
      "chapter": null,
      "chapter_title": "",
      "page_number": 24
    }
  },
  {
    "text": "--- Page 25 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\n1\nThe History of Diabetes Mellitus\nRobert B. Tattersall\nUniversity of Nottingham, Nottingham, UK\nKeypoints\n(cid:129) Polyuric diseases have been described for over 3500 years. The name (cid:129) The primary sequence of insulin was reported in 1955 by Sanger and\n“ diabetes” comes from the Greek word for a syphon; the sweet taste the three- dimensional structure by Hodgkin in 1969. Proinsulin was\nof diabetic urine was recognized at the beginning of the fi rst discovered by Steiner in 1967, and the sequence of the human insulin\nmillennium, but the adjective “ mellitus ” (honeyed) was only added by gene by Bell in 1980. Yalow and Berson invented the\nRollo in the late 18th century. radioimmunoassay for insulin in 1956.",
    "chunk_id": 64,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 844
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 25
    }
  },
  {
    "text": "The presence of insulin receptors\n(cid:129) The sugar in diabetic urine was identifi ed as glucose by Chevreul in was deduced in 1971 by Freychet, and the receptor protein was\n1815. In the 1840s, Bernard showed that glucose was normally present isolated in 1972 by Cuatrecasas. in blood, and showed that it was stored in the liver (as glycogen) for (cid:129) The various types of diabetic retinopathy were described in the second\nsecretion into the bloodstream during fasting. half of the 19th century as were the symptoms of neuropathy. (cid:129) In 1889, Minkowski and von Mering reported that pancreatectomy Albuminuria was noted as a common abnormality in patients with\ncaused severe diabetes in the dog. In 1893, Laguesse suggested that diabetes in the 19th century and a unique type of kidney disease was\nthe pancreatic “ islets ” described by Langerhans in 1869 produced an described in 1936 by Kimmelstiel and Wilson.",
    "chunk_id": 65,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 925
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 25
    }
  },
  {
    "text": "The concept of a specifi c\ninternal secretion that regulated glucose metabolism. diabetic angiopathy was developed by Lundbaek in the early 1950s. (cid:129) Insulin was discovered in 1921 by Banting, Best, Macleod and Collip in (cid:129) Milestones in insulin pharmacology have included the invention of\nacid- ethanol extracts of pancreas. It was fi rst used for treatment in delayed- action preparations in the 1930s and 1940s; synthetic human\nJanuary 1922. insulin in 1979; and in the 1990s novel insulin analogs by recombinant\n(cid:129) Diabetes was subdivided on clinical grounds into diab è te maigre (lean DNA technology. subjects) and diab è te gras (obese) by Lancereaux in 1880, and during (cid:129) The fi rst sulfonylurea carbutamide was introduced in 1955, followed by\nthe 1930s by Falta and Himsworth into insulin- s ensitive and insulin- tolbutamide in 1957 and chlorpropamide in 1960. The biguanide\ninsensitive types.",
    "chunk_id": 66,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 932
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 25
    }
  },
  {
    "text": "These classifi cations were the forerunners of the phenformin became available in 1959 and metformin in 1960. etiological classifi cation into type 1 (insulin- d ependent) and type 2 (cid:129) That improved glucose control in both type 1 and type 2 diabetes was\n(non - insulin - dependent) diabetes. benefi cial was proved by the Diabetes Control and Complications Trial\n(cid:129) Insulin resistance and β - cell failure, the fundamental defects of type 2 (1993) and the UK Prospective Diabetes Study (1998). diabetes, have been investigated by many researchers. The “ i nsulin (cid:129) Landmarks in the treatment of complications include photocoagulation\nclamp” method devised by Andres and DeFronzo was the fi rst accurate for retinopathy fi rst described by Meyer - Schwickerath; the importance\ntechnique for measuring insulin action.",
    "chunk_id": 67,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 838
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 25
    }
  },
  {
    "text": "Maturity- o nset diabetes of the of blood pressure to slow the progression of nephropathy\nyoung was described as a distinct variant of type 2 diabetes by (demonstrated by Mogensen and Parving); the introduction of low - dose\nTattersall in 1974. insulin in the treatment of diabetic ketoacidosis in the 1970s; and\n(cid:129) Lymphocytic infi ltration of the islets (insulitis) was described as early as improvements in the care of pregnant women with diabetes pioneered\n1901 and highlighted in 1965 by Gepts who suggested that it might by White and Pedersen. be a marker of autoimmunity. Islet cell antibodies were discovered by\nDoniach and Bottazzo in 1979. in an Egyptian papyrus dating from c. 1550 bc , discovered by\nAncient t imes Georg Ebers (Figure 1.1 ), and a clearly recognizable description\nof what would now be called type 1 diabetes was given by Aretaeus\nDiseases with the cardinal features of diabetes mellitus were rec- of Cappadocia in the 2nd century a d (Figure 1.2 a).",
    "chunk_id": 68,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 985
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 25
    }
  },
  {
    "text": "Aretaeus was\nognized in antiquity (Table 1.1 ). A polyuric state was described the fi rst to use the term “ diabetes, ” from the Greek word for a\nsyphon, “ because the fl uid does not remain in the body, but uses\nTextbook of Diabetes, 4th edition. Edited by R. Holt, C. Cockram, the man ’ s body as a channel whereby to leave it. ” His graphic\nA. Flyvbjerg and B. Goldstein. © 2010 Blackwell Publishing. account of the disease highlighted the incessant fl ow of urine,\n3",
    "chunk_id": 69,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 470
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 25
    }
  },
  {
    "text": "--- Page 26 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nTable 1.1 Milestones in the clinical descriptions of diabetes and its\ncomplications.",
    "chunk_id": 70,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 205
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 26
    }
  },
  {
    "text": "Clinical features of diabetes\nEbers papyrus (Egypt, 1500 B C ) Polyuric state\nSushrut and Charak (India, 5th Sugary urine; thin and obese\ncentury BC ) patients distinguished\nAretaeus (Cappadocia, 2nd Polyuric state named “ diabetes ”\ncentury A D )\nChen Chuan (China, 7th century) Sugary urine\nAvicenna (Arabia, 10th century A D ) Sugary urine; gangrene and\nimpotence as complications\nDiabetic ketoacidosis\nWilliam Prout (England, Diabetic coma\n1810 – 1820)\nAdolf Kussmaul (Germany, 1874) Acidotic breathing\nHyperlipidemia\nAlbert Heyl (Philadelphia, 1880) Lipemia retinalis\nRetinopathy\nEduard von Jaeger (Germany, 1855) General features\nStephen Mackenzie and Edward Microaneurysms\nNettleship (England, 1879)\nEdward Nettleship (England, 1888) New vessels, beading of retinal veins\nFigure 1.1 The Ebers papyrus. Courtesy of the Wellcome Library, London.",
    "chunk_id": 71,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 850
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 26
    }
  },
  {
    "text": "Julius Hirschberg (Germany, 1890) Classifi cation of lesions; specifi c to\ndiabetes\nNeuropathy and foot disease\nJohn Rollo (England, 1797) Neuropathic symptoms\nMarchal de Calvi (France, 1864) Neuropathy is a complication of (b)\ndiabetes\nWilliam Ogle (England, 1866) Ocular nerve palsies in diabetes\nFrederick Pavy (England, 1885) Peripheral neuropathy\nJulius Althaus (Germany, 1890) Mononeuropathy\nThomas Davies Pryce (England, Perforating foot ulcers\n1887)\nNephropathy\nWilhelm Griesinger (Germany, Renal disease in patients with\n1859) diabetes\nPaul Kimmelstiel and Clifford Wilson Glomerulosclerosis associated with\n(USA, 1936) heavy proteinuria\n(a)\nDiabetes is a dreadful affliction, not very frequent among\nmen, being a melting down of the flesh and limbs into\nurine. The patients never stop making water and the flow is\nincessant, like the opening of aqueducts.",
    "chunk_id": 72,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 865
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 26
    }
  },
  {
    "text": "Life is short,\nunpleasant and painful, thirst unquenchable, drinking\nexcessive, and disproportionate to the large quantity of\nurine, for yet more urine is passed. One cannot stop them\neither from drinking or making water. If for a while they\nabstain from drinking, their mouths become parched and\ntheir bodies dry; the viscera seem scorched up, the patients\nare affected by nausea, restlessness and a burning thirst, and\nwithin a short time, they expire. Figure 1.2 (a) Clinical description of diabetes by Aretaeus of Cappadocia (2nd century A D ). Adapted from Papaspyros NS (1952) T he History of Diabetes Mellitus . (b) Sushrut (Susrata), an Indian physician who wrote medical texts with Charak (Charuka) between 500 B C and 400 BC . 4",
    "chunk_id": 73,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 738
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 26
    }
  },
  {
    "text": "--- Page 27 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\nunquenchable thirst, the “ melting down of the fl esh and limbs “ diabetes was a disease so rare among the ancients that many\ninto urine ” and short survival. famous physicians made no mention of it … but in our age, given\nThe Hindu physicians, Charak and Sushrut, who wrote between to good fellowship and guzzling down of unallayed wine, we meet\n400 and 500 b c , were probably the fi rst to recognize the sweetness with examples and instances enough, I may say daily, of this\nof diabetic urine (Figure 1.2 b). Indeed, the diagnosis was made disease. ” He described the urine as being “ wonderfully sweet like\nby tasting the urine or noting that ants congregated round it. sugar or honey ” but did not consider that this might be because\nCharak and Sushrut noted that the disease was most prevalent in it contained sugar.",
    "chunk_id": 74,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 982
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 27
    }
  },
  {
    "text": "those who were indolent, overweight and gluttonous, and who The fi rst description of hyperglycemia was in a paper published\nindulged in sweet and fatty foods. Physical exercise and liberal in 1776 by Matthew Dobson (1735 – 1784) of Liverpool (Figure\nquantities of vegetables were the mainstays of treatment in the 1.3 ) [2] . He found that the serum as well as the urine of his patient\nobese, while lean people, in whom the disease was regarded as Peter Dickonson (who passed 28 pints of urine a day) tasted\nmore serious, were given a nourishing diet. The crucial fact that sweet. Moreover, he evaporated the urine to “ a white cake [which]\ndiabetic urine tasted sweet was also emphasized by Arabic medical smelled sweet like brown sugar, neither could it by the taste be\ntexts from the 9 – 11th centuries a d , notably in the medical ency- distinguished from sugar. ” Dobson concluded that the kidneys\nclopedia written by Avicenna (980 – 1037).",
    "chunk_id": 75,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 946
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 27
    }
  },
  {
    "text": "excreted sugar and that it was not “ formed in the secretory organ\nbut previously existed in the serum of the blood.”\nThe Edinburgh - trained surgeon, John Rollo (d . 1809) was the\nThe 17th and 18th c enturies fi rst to apply the adjective “ mellitus ” (from the Latin word\nmeaning “ honey ” ). He also achieved fame with his “ animal diet, ”\nIn Europe, diabetes was neglected until Thomas Willis (1621 – which became the standard treatment for most of the 19th\n1675) wrote Diabetes, or the Pissing Evil [1] . According to him, century. Rollo thought that sugar was formed in the stomach\nFigure 1.3 F rontispiece and opening page of the paper by Matthew Dobson (1776), in which he described the sweet taste of both urine and serum from a patient with\ndiabetes [2] . 5",
    "chunk_id": 76,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 767
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 27
    }
  },
  {
    "text": "--- Page 28 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nFigure 1.5 C laude Bernard (1813 – 1878). Courtesy of the Wellcome Institute\nLibrary, London. Figure 1.4 Extract from John Rollo ’ s account of two cases of diabetes (1797). Rollo was well aware of the problem of non- c ompliance. Note that “t he patient\nintroduced by Trommer in 1841, Moore in 1844 and – the best\nwas strongly remonstrated with, and told of the consequences of repeated\nknown – Fehling in 1848. Measurement of blood glucose could\ndeviations. ” Courtesy of the Wellcome Library, London. only be done by skilled chemists but needed so much blood that\nit was rarely used in either clinical care or research. It only became\nfrom vegetables, and concluded that the obvious solution was a practicable with the introduction in 1913 of a micromethod by\ndiet of animal food.",
    "chunk_id": 77,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 957
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 28
    }
  },
  {
    "text": "Thus, the regimen described in his 1797 the Norwegian - born physician Ivar Christian Bang (1869 – 1918)\nbook, An Account of Two Cases of the Diabetes Mellitus [3] , and it was the ability to measure glucose repeatedly which led to\nallowed his patient Captain Meredith to have for dinner “ Game development of the glucose tolerance test between 1913 and 1915. or old meats which have been long kept; and as far as the stomach Glucose metabolism was clarifi ed by the work of Claude\nmay bear, fat and rancid old meats, as pork. ” Rollo was probably Bernard (1813 – 1878) [5] , the Frenchman whose numerous dis-\nthe fi rst to note the diffi culty that some patients fi nd in adhering coveries have given him a special place in the history of physiol-\nto treatment – a diffi culty he blamed for the death of his second ogy (Figure 1.5 ). When Bernard began work in 1843, the prevailing\npatient (Figure 1.4 ).",
    "chunk_id": 78,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 905
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 28
    }
  },
  {
    "text": "theory was that sugar could only be synthesized by plants, and\nthat animal metabolism broke down substances originally made\nin plants. It was also thought that the blood only contained sugar\nThe 19th c entury after meals, or in pathologic states such as diabetes. Between 1846\nand 1848, Bernard reported that glucose was present in the blood\nIn 1815, the French chemist Michel Chevreul (1786 – 1889) proved of normal animals, even when starved. He also found higher\nthat the sugar in diabetic urine was glucose [4] . In the middle of concentrations of glucose in the hepatic than in the portal vein,\nthe century, tasting the urine to make the diagnosis was super- and “ enormous quantities ” of a starch - like substance in the liver\nseded by chemical tests for reducing agents such as glucose as which could be readily converted into sugar. He called this “ gly-\n6",
    "chunk_id": 79,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 865
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 28
    }
  },
  {
    "text": "--- Page 29 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\nFigure 1.7 Paul Langerhans (1847 – 1888). Courtesy of the Wellcome Institute\nLibrary, London. that the dog, previously house - trained, was now incontinent of\nurine. Minkowski realized the signifi cance of the polyuria, and\ntested the dog ’ s urine. Possible explanations for the role of the pancreas were that it\nremoved a diabetogenic toxin, or produced an internal secretion\nFigure 1.6 Oskar Minkowski (1858 – 1931). that controlled carbohydrate metabolism. The concept of\n“ internal secretions ” had been publicized in June 1889, by the\ncogen ” (i.e. sugar - forming) and regarded it as analogous to starch well - known physiologist Charles - É douard Brown - S é quard\nin plants.",
    "chunk_id": 80,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 844
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 29
    }
  },
  {
    "text": "His hypothesis – the “ glycogenic ” theory – was that (1817– 1894), who claimed to have rejuvenated himself by injec-\nsugar absorbed from the intestine was converted in the liver into tions of testicular extract [9] . It was given further credence in\nglycogen and then constantly released into the blood during 1891, when Murray reported that myxoedema could be cured by\nfasting. sheep thyroid extract by injection or orally. A nother discovery by Bernard made a great impression in an In 1893, Gustave Laguesse suggested that the putative internal\nera when the nervous control of bodily functions was a scientifi - secretion of the pancreas was produced by the “ islands ” of cells\ncally fashionable concept. He found that a lesion in the fl oor of scattered through the gland’ s parenchyma [ 10], which had been\nthe fourth ventricle produced temporary hyperglycemia ( piq û re discovered in 1869 by the 22 - year - old Paul Langerhans (1847 –\ndiabetes) [ 6].",
    "chunk_id": 81,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 960
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 29
    }
  },
  {
    "text": "This fi nding spawned a long period in which 1888) (Figure 1.7 ). Langerhans had described these clusters of\nnervous infl uences were thought to be important causes of dia- cells, having teased them out from the general pancreatic tissue,\nbetes; indeed, one piece of “ evidence ” – cited by J.J.R. Macleod but had not speculated about their possible function [11] ; it was\nas late as 1914 – was that diabetes was more common among Laguesse who named them the “ islets of Langerhans. ” At this\nengine drivers than other railway workers because of the mental time, the glucose - lowering internal secretion of the islets was still\nstrain involved [7] . hypothetical, but in 1909 the Belgian Jean de Meyer named it\nIn the fi rst part of the 19th century the cause of diabetes was a insuline (from the Latin for “ island ” ) [12] . mystery, because autopsy usually did not show any specifi c It would be wrong to give the impression that Minkowski ’ s\nlesions.",
    "chunk_id": 82,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 956
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 29
    }
  },
  {
    "text": "A breakthrough came in 1889 when Oskar Minkowski experiments immediately established the pancreatic origin of dia-\n(Figure 1.6 ) and Josef von Mering (1849 – 1908) reported that betes. In fact, during the next two decades, it was widely agreed\npancreatectomy in the dog caused severe diabetes [ 8]. This was that diabetes was a heterogeneous disorder with various subtypes,\nserendipitous, because they were investigating fat metabolism; it and that its pathogenesis involved at least three organs: the brain,\nis said that the laboratory technician mentioned to Minkowski pancreas and liver [13] . The discovery by Blum in 1901 that injec-\n7",
    "chunk_id": 83,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 640
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 29
    }
  },
  {
    "text": "--- Page 30 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nFigure 1.8 P ictures from J aeger ’ s Atlas of the\nOptic Fundus , 1869 [14] . Top left: Bright ’ s disease. Top right: Jaeger ’ s retinitis hemorrhagica is now\nrecognized as central retinal vein occlusion. Bottom\nleft: A 22 -y ear - old man with suspected diabetes. Bottom right: Central retinal artery occlusion. Courtesy of W.B. Saunders. tion of an adrenal extract caused glycosuria implicated other more like hypertensive retinopathy. In 1879, Stephen Mackenzie\nglands, and led to the “ polyglandular theory ” of Carl von Noorden (1844– 1909) and Sir Edward Nettleship (1845 – 1913) found\n(Vienna), who proposed that the thyroid, pancreas, adrenals and microaneurysms in fl at preparations of the retina and, in 1888,\nparathyroids controlled carbohydrate metabolism.",
    "chunk_id": 84,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 944
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 30
    }
  },
  {
    "text": "Nettleship described new vessels and the beaded appearance of\nretinal veins [15] . The full picture of diabetic retinopathy was\nClinical d iabetes in the 19th c entury described in 1890 by Julius Hirschberg (1843 – 1925) who was the\nDoctors in the 19th century were therapeutically impotent; their fi rst to claim that it was specifi c to diabetes [ 16]. main role was as taxonomists who described symptom complexes Neuropathic symptoms in patients with diabetes had been\nand the natural history of disease. As a result, most of the major mentioned by Rollo at the end of the 18th century, and in 1864\ncomplications of diabetes were well described before 1900. Charles Marchal de Calvi (1815 – 1873) concluded that nerve\nEduard von Jaeger (1818 – 1884) is credited with the fi rst damage was a specifi c complication of diabetes.",
    "chunk_id": 85,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 829
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 30
    }
  },
  {
    "text": "In 1885, the\ndescription of diabetic retinopathy, in his beautiful Atlas of Guy ’ s Hospital physician, Frederick Pavy (1829 – 1911), gave a\nDiseases of the Ocular Fundus , published in 1869 [14] . In fact, the description of neuropathic symptoms which would grace any\nfeatures illustrated (Figure 1.8 ), from a 22 - year - old patient, look modern textbook [ 17]:\n8",
    "chunk_id": 86,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 366
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 30
    }
  },
  {
    "text": "--- Page 31 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\n“ The usual account given by these patients of their condition is that features of diabetic kidney disease and the importance of renal\nthey cannot feel properly in their legs, that their feet are numb, that complications were not reported until the 1930s. their legs seem too heavy – as one patient expressed it, “ as if he had In the latter part of the 19th century it was becoming apparent\n20 l b weights on his legs and a feeling as if his boots were great deal that there were at least two clinically distinct forms of diabetes. too large for his feet. ” Darting or “ lightning ” pains are often com- In 1880, the French physician Etienne Lancereaux (1829 – 1910)\nplained of.",
    "chunk_id": 87,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 839
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 31
    }
  },
  {
    "text": "Or there may be hyperaesthesia, so that a mere pinching identifi ed lean and obese patients as having diab è te maigre and\nof the skin gives rise to great pain; or it may be the patient is unable diab è te gras [20] , and this observation laid the foundations for\nto bear the contact of the seam of the dress against the skin on account subsequent etiologic classifi cations of the disease. of the suffering it causes. Not infrequently there is deep- s eated pain\nlocated, as the patient describes it, in the marrow of the bones which\nare tender on being grasped, and I have noticed that these pains are The 20th c entury\ngenerally worse at night.",
    "chunk_id": 88,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 647
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 31
    }
  },
  {
    "text": "”\nMurray ’ s cure of myxoedema in 1891 led to a belief that pancre-\nPavy also recorded unusual presentations, including a 67 - year - atic extract would soon result in a cure for diabetes, but, in the\nold who complained of “ lightning pains on the right side of the face of repeated failures over the next 30 years, even believers in\nwaist ” and cases in which the third nerve was affected with an antidiabetic internal secretion were depressed about the likeli-\n“ dropped lid and external squint ” [18] . hood of isolating it, and diverted their attention to diet as a treat-\nKidney disease was known to be relatively common in diabetes. ment for the disease.",
    "chunk_id": 89,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 660
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 31
    }
  },
  {
    "text": "In 1859, Wilhelm Griesinger (1817 – 1868) reported 64 autopsies Best known was the starvation regimen of Frederick Madison\nin adults, half of whom had renal changes which he attributed to Allen (1876 – 1964), which Joslin (Figure 1.9 ) described in 1915 as\nhypertension and atherosclerosis [19] ; however, the histologic the greatest advance since Rollo ’ s time [21] . This approach was\n(a) (b)\nFigure 1.9 E lliott P. Joslin (1869 – 1962), arguably the most famous diabetes specialist of the 20th century and the frontispiece to his 1916 textbook [22] . Courtesy of\nthe Wellcome Library, London. 9",
    "chunk_id": 90,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 598
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 31
    }
  },
  {
    "text": "--- Page 32 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nan extreme application of one that had been proposed as early as Thompson, who had been on the Allen starvation regimen since\n1875 by Apollinaire Bouchardat (1806 – 1886), who advocated 1919 and weighed only 30 kg (Figure 1.12 ). After the fi rst injec-\nintensive exercise and “ manger le moins possible . ” Starvation tion, his blood glucose level fell slightly, but his symptoms were\ntreatment did work in a limited sense, in that some patients could unchanged and he developed a sterile abscess. On January 23, he\nsurvive for many months or even years, instead of a few weeks or was given another extract prepared by Collip, and this normalized\nmonths with untreated type 1 diabetes.",
    "chunk_id": 91,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 860
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 32
    }
  },
  {
    "text": "The quality of life, his blood glucose by the next morning; further injections over the\nhowever, was very poor, and some patients died of malnutrition next 10 days led to marked clinical improvement and complete\nrather than diabetes. In 1921, Carl von Noorden (1858 – 1944) – elimination of glycosuria and ketonuria. Initial clinical results in\nproponent of the “ oatmeal cure ” – turned away in disapproval seven cases were published in the March 1922 issue of the\nwhen he saw Joslin ’ s prize patient, 17 - year - old Ruth A, who at Canadian Medical Association Journal [27] , which concluded\njust over 1.52 m in height weighed only 24.5 kg (a body mass dramatically that:\nindex of 10.6 kg/m 2 ). 1 Blood sugar can be markedly reduced, even to normal\nvalues;\nDiscovery of i nsulin 2 Glycosuria can be abolished;\nMany attempts were made between 1889 and 1921 to isolate the 3 T he acetone bodies can be made to disappear from the\nelusive internal secretion of the pancreas.",
    "chunk_id": 92,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 974
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 32
    }
  },
  {
    "text": "These largely failed urine;\nbecause the extracts were inactive or had unacceptable side 4 The respiratory quotient shows evidence of increased utiliza-\neffects; some preparations may have had limited biologic activity, tion of carbohydrates;\nbut this was not recognized, either because hypoglycemia was 5 A defi nite improvement is observed in the general condition\nmisinterpreted as a toxic reaction or because blood glucose was of these patients and, in addition, the patients themselves report\nnot measured. Those who came closest were the Berlin physician, a subjective sense of well - being and increased vigor for a period\nGeorg Zuelzer (1840 – 1949) in 1907 [23] , Ernest Scott (1877 – following the administration of these preparations. 1966) in Chicago in 1911 [24] and Nicolas Paulesco (1869 – 1931) The term “ insulin ” was coined by Macleod, who was unaware\nin Romania in 1920 – 1921 [25] (Figure 1.10 ). of de Meyer ’ s earlier suggestion of insuline .",
    "chunk_id": 93,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 965
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 32
    }
  },
  {
    "text": "News of its miracu-\nThe story of how insulin was discovered in Toronto in 1921 is lous effects spread astonishingly rapidly [28] . In 1922, there were\nwell known, at least superfi cially (Figure 1.11 ). A young ortho- only 19 references in the world literature to “ insulin ” or equiva-\npedic surgeon, Frederick Banting, inspired after reading an article lent terms such as “ pancreatic extract ” ; by the end of 1923, there\nby the pathologist Moses Barron (1884 – 1975), wondered whether were 320 new reports, and a further 317 were published during\nthe antidiabetic pancreatic principle was digested by trypsin the fi rst 6 months of 1924. during extraction, and decided to prevent this loss by ligating By October 1923, insulin was available widely throughout\nthe pancreatic duct, thus causing the exocrine tissue to dege- North America and Europe. International recognition followed\nnerate.",
    "chunk_id": 94,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 894
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 32
    }
  },
  {
    "text": "He approached the Professor of Physiology in Toronto, rapidly for its discoverers, and the 1923 Nobel Prize for Physiology\nJ.J.R. Macleod, an authority on carbohydrate metabolism, who or Medicine was awarded jointly to Banting and Macleod. Banting\npoured scorn on the idea and suggested that the only likely was angered by the decision, and announced publicly that he\noutcome would be “ a negative result of great physiological would share his prize with Best, whereupon Macleod decided to\nimportance. ” do the same with Collip. Eventually, Macleod relented and installed Banting in a\nrundown laboratory, later leaving for Scotland and a fi shing The p ostinsulin e ra\nholiday. A student, Charles Best, was chosen by the toss of a coin It was confi dently anticipated that insulin would do for diabetes\nto help Banting.",
    "chunk_id": 95,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 819
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 32
    }
  },
  {
    "text": "Within 6 months of this unpromising start, in the young what thyroid extract had done for myxoedema, but\nBanting and Best (referred to in Toronto academic circles as B 2 ) it soon became obvious that insulin was a very different type of\nhad discovered the most important new therapy since the treatment. Thyroid was given once a day by mouth and at a fi xed\nantisyphilitic agent Salvarsan. These events are described in detail dosage. Insulin had to be injected in measured amounts which\nin the excellent book by Michael Bliss [ 26]. varied from day to day, and carried the ever - present danger of\nT heir approach began with the injection of extracts of atro- hypoglycemia. One often reads that insulin “ revolutionized ” the\nphied pancreas (prepared according to Macleod ’ s suggestions) treatment of diabetes; it did so in the sense that it saved the lives\ninto dogs rendered diabetic by pancreatectomy).",
    "chunk_id": 96,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 907
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 32
    }
  },
  {
    "text": "Subsequently, of many who would otherwise have died, but its unforeseen effect\nthey discovered that active extracts could be obtained from beef was to transform an acute, rapidly fatal illness into a chronic\npancreas which Best obtained from the abbatoir. The extraction disease with serious long - term complications. For example, only\nprocedure (using ice - cold acid - ethanol) was greatly refi ned by 2% of deaths among Joslin’ s young patients with diabetes before\nJames B. (Bert) Collip, a biochemist who was visiting Toronto on 1937 were caused by kidney disease, while over 50% dying\nsabbatical leave. between 1944 and 1950 had advanced renal failure. Strategies to\nThe fi rst clinical trial of insulin (using an extract made by avoid and prevent the chronic complications of diabetes remain\nBest) took place on January 11, 1922, on 14 - year - old Leonard important scientifi c and clinical priorities today. 10",
    "chunk_id": 97,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 920
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 32
    }
  },
  {
    "text": "--- Page 33 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\n(a) (b)\n(c)\nFigure 1.10 (a) Georg Zuelzer (1840 – 1949) and (b) the title page from his paper (1907) reporting that a pancreatic extract reduced glycosuria in pancreatectomized\ndogs [23] (top). (c) Nicolas Paulesco (1869– 1 931). The rest of this chapter highlights some developments Causes and n atural h istory of d iabetes\nthat can be regarded as landmarks in the understanding The recognition that diabetes was not a single disease was impor-\nand management of the disease: to some extent, this is a tant in initiating research that has helped to unravel the causes of\npersonal choice, and it is obvious from the other chapters in hyperglycemia. this book that the “ history ” of diabetes is being rewritten all The broad etiologic subdivision into type 1 (juvenile - onset, or\nthe time.",
    "chunk_id": 98,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 951
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 33
    }
  },
  {
    "text": "insulin - dependent) and type 2 diabetes (maturity - onset, or\n11",
    "chunk_id": 99,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 65
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 33
    }
  },
  {
    "text": "--- Page 34 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nFigure 1.11 The discoverers of insulin. Clockwise\nfrom top left: Frederick G. Banting (1891 – 1941);\nJames B. Collip (1892 – 1965); J.J.R. Macleod\n(1876 – 1935); and Charles H. Best (1899 – 1978). Courtesy of the Fisher Rare Book Library, University\nof Toronto. non - insulin - dependent) stemmed ultimately from Lancereaux ’ s\ndiab è te maigre and d iab è te gras distinction, as well as observations\nsoon after the discovery of insulin that some patients did not react\n“ normally ” to insulin. In the 1930s, Wilhelm Falta (1875 – 1950)\nin Vienna [29] and Harold Himsworth (1905 – 93) in London [30]\nproposed that some individuals with diabetes were more sensitive\nto the glucose - lowering effects of insulin, whereas others were\ninsulin - insensitive, or insulin - resistant.",
    "chunk_id": 100,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 952
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 34
    }
  },
  {
    "text": "The former were usually\nthin and required insulin to prevent ketoacidosis, while the latter\nwere older, obese and ketosis - resistant. The “ insulin clamp ” technique developed in the 1970s by\nRalph DeFronzo e t al . [31] in the USA was the fi rst to measure\nrigorously the hypoglycemic action of insulin, and has led to\ncountless studies of insulin resistance and its relationship to type\n2 diabetes and vascular disease. Various groups, including\nDeFronzo ’ s, have helped to clarify the role of β- c ell failure in type\n2 diabetes, and how it relates to insulin resistance. Maturity - onset\ndiabetes of the young (MODY) was recognized in 1974 by Robert\nTattersall ( b. 1943) as a distinct, dominantly inherited subset of\nFigure 1.12 Leonard Thompson, the fi rst patient to receive insulin, in January type 2 diabetes [32] ; since 1993, fi ve different molecular defects\n1922. Courtesy of the Fisher Rare Book Library, University of Toronto. have been identifi ed in this condition. 12",
    "chunk_id": 101,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 987
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 34
    }
  },
  {
    "text": "--- Page 35 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\nThe causes of the profound β- c ell loss that led to the severe\nTable 1.2 Milestones in the scientifi c understanding of diabetes and its\ninsulin defi ciency of type 1 diabetes remained a mystery for a long\ncomplications. time. “ Insulitis ” , predominantly lymphocytic infi ltration of the\nislets, was noted as early as 1901 by Eugene L. Opie (1873 – 1971) Matthew Dobson (England, 1776) Diabetic serum contains sugar\nand colleagues [33] , but because it was apparently very rare, Michel Chevreul (France, 1815) The sugar in diabetic urine is glucose\nfound in only six of 189 cases studied by Anton Weichselbaum Claude Bernard (France, 1850s) Glucose stored in liver glycogen and\n(1845 –1 920) in 1910, its importance was not appreciated.",
    "chunk_id": 102,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 899
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 35
    }
  },
  {
    "text": "The secreted during fasting\npossible role of insulitis in β - cell destruction was not suggested Wilhelm Petters (Germany, 1857) Diabetic urine contains acetone\nuntil 1965, by the Belgian Willy Gepts (1922 – 1991) [34] . The Paul Langerhans (Germany, 1869) Pancreatic islets described\nAdolf Kussmaul (Germany, 1874) Describes ketoacidosis\ntheory that type 1 diabetes results from autoimmune destruction\nof the β cells was fi rst made in 1979 by Deborah Doniach (1912 – Oskar Minkowski and Josef von Pancreatectomy causes diabetes in the\nMering (Germany, 1889) dog\n2004) and GianFranco Bottazzo ( b. 1946) [35] . Unlike other\nGustave Edouard Laguesse (France, Glucose - lowering pancreatic secretion\nautoimmune endocrine diseases where the autoantibody persists,\n1893) produced by islets\nislet cell antibodies (ICA) turned out to be transient and disap-\nM.A. Lane (USA, 1907) Distinguished A and B islet cells\npeared within a year of the onset of diabetes.",
    "chunk_id": 103,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 955
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 35
    }
  },
  {
    "text": "An unexpected Jean de Meyer (Belgium, 1909) Hypothetical islet secretion named\nfi nding from the Barts – Windsor prospective study of the epide- “i nsuline ”\nmiology of diabetes in childhood started by Andrew Cudworth Frederick Banting, Charles Best, Isolation of insulin\n(1939 – 1982) was that ICA could be detected in siblings of young J.J.R. Macleod, James Collip\npeople with diabetes up to 10 years before they developed appar- (Canada, 1922)\nently acute - onset diabetes. This long lead - in period raised the Richard Murlin (USA, 1923) Discovered and named glucagon\npossibilty of an intervention to prevent continuing β - cell destruc- Bernado Houssay (Argentina, 1924) Hypophysectomy enhances insulin\nsensitivity\ntion. Cyclosporine in people with newly diagnosed type 1 diabetes\nFrederick Sanger (England, 1955) Determined primary sequence of\nprolongs the honeymoon period but without permanent benefi t\ninsulin\nonce the drug is stopped [36] . Nicotinamide and small doses of\nW.W.",
    "chunk_id": 104,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 987
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 35
    }
  },
  {
    "text": "Bromer (USA, 1956) Determined primary sequence of\ninsulin (together with many other interventions) prevent diabetes\nglucagon\nin the non - obese diabetic (NOD) mouse but were without effect Rosalyn Yalow and Solomon Berson Discovered radioimmunoassay for\nin relatives of people with type 1 diabetes with high titers of ICA (USA, 1959) insulin\n[37,38] . Donald Steiner (USA, 1967) Discovered proinsulin\nFrom 1967, when Paul Lacy (1924 – 2005) showed that it was Dorothy Hodgkin (England, 1969) Determined three - dimensional\npossible to “ c ure” diabetes in inbred rats with an islet cell trans- structure of insulin\nplant, it always seemed that the problem of islet cell transplanta- Pierre Freychet (USA, 1971) Characterized insulin receptors\nPedro Cuatrecasas (USA, 1972) Isolated insulin receptor protein\ntion in humans was about to be solved. Hope was rekindled in\nAxel Ullrich (USA, 1977) Reported sequence of rat insulin\n2000 by a team in Edmonton, Canada.",
    "chunk_id": 105,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 961
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 35
    }
  },
  {
    "text": "After 5 years 80% of their\nRalph DeFronzo and Reuben Andres Invented insulin clamp technique\ntransplanted patients were producing some endogenous insulin\n(USA, 1979)\nbut only 10% could manage without any injected insulin [39] . Graham Bell (USA, 1980) Reported sequence of human\ninsulin gene\nChronic d iabetic c omplications\nIt had been assumed that arteriosclerosis caused chronic diabetic\ncomplications, but this notion was challenged by two papers pub-\nlished in the mid - 1930s, which pointed to specifi c associations of tures of hypertension, heavy albuminuria with “ oedema of the\ndiabetes with retinal and renal disease (Table 1.2 ). In 1934, Henry nephrotic type,” and renal failure.",
    "chunk_id": 106,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 692
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 35
    }
  },
  {
    "text": "In fact, this paper led to con-\nWagener (1890 – 1961) and Russell Wilder (1885 – 1959) from the siderable confusion during the next 15 years: according to one\nMayo Clinic reported patients who had retinal hemorrhages but writer, the “ Kimmelstiel – Wilson syndrome ” came to mean all\nno other clinical evidence of vascular disease [40] , and concluded things to all men [42] . Nonetheless, it was signifi cant because it\nthat “ The very existence of retinitis in cases in which patients have drew attention to a specifi c diabetic renal disease. no other signs of vascular disease must mean that diabetes alone Acceptance of the concept that diabetic angiopathy was specifi c\ndoes something to injure the fi ner arterioles or venules of the to the disease owed much to the work of Knud Lundb æ k of\nretina, probably the latter.",
    "chunk_id": 107,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 827
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 35
    }
  },
  {
    "text": "” Aarhus in Denmark (Figure 1.14 ), who published his fi ndings in\nIn 1936, Paul Kimmelstiel (1900 – 1970) and Clifford Wilson a book in 1953 – 1954 and a paper in the Lancet in 1954 [43,44] . (1906 – 1997) described the striking histologic fi nding of “ inter- His key arguments were that long - standing diabetic vascular\ncapillary glomerulosclerosis ” – large hyaline nodules in the disease differed fundamentally from atherosclerosis, in that both\nglomeruli – in the kidneys of eight subjects at autopsy (Figure sexes were equally affected and that microaneurysms, ocular\n1.13 ) [41] . Seven of the eight patients had a known history of phlebopathy and Kimmelstiel – Wilson nodules were unique to\ndiabetes, and Kimmelstiel and Wilson noted the common fea- diabetes and usually occurred together. 13",
    "chunk_id": 108,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 802
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 35
    }
  },
  {
    "text": "--- Page 36 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nFigure 1.13 Nodular glomerulosclerosis. Figure from the paper by Kimmelstiel\nFigure 1.14 Knud Lundb æ k (1912 – 1995). Courtesy of Dr Carl Erik Mogensen. and Wilson, 1936 [41] . Courtesy of the British Medical Association Library. T he molecular and cellular mechanisms underlying diabetic\nTable 1.3 Milestones in the understanding of the causes of diabetes. tissue damage remain controversial after decades of intensive\nresearch. One of the early landmarks in this fi eld was the work of\nThomas Willis (England, 17th Overindulgence in food and drink\nJ.H. Kinoshita (b . 1922) during the early 1970s, which pointed to\ncentury)\nthe involvement of the polyol pathway in the formation of dia- Thomas Cawley (England, 1788) Pancreatic stones cause diabetes\nbetic cataracts [45] .",
    "chunk_id": 109,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 949
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 36
    }
  },
  {
    "text": "Oskar Minkowski and Josef von Pancreatectomy causes diabetes in\nMering (Germany, 1889) the dog\nPhysiology Etienne Lancereaux (France, 1880) Lean and obese diabetic subtypes\nIn 1907, M.A. Lane, a student of Robert Bensley (1867 – 1956), distinguished\nProfessor of Antatomy in Chicago, used conventional histologic Eugene Opie (USA, 1900) Hyaline degeneration (amyloidosis) of\nislets (type 2 diabetes)\ntechniques to distinguish two different cell types in the islet of\nEugene Opie (USA, 1910) Lymphocytic infi ltration of islets\nLangerhans, which he termed A and B [46] . The hormones\n( “ insulitis ” ; type 1 diabetes)\nsecreted by these respective cell types were not identifi ed until\nWilhelm Falta (Vienna) and Harold Distinguished insulin - resistant and\nmuch later (Table 1.2 ).",
    "chunk_id": 110,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 781
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 36
    }
  },
  {
    "text": "Frank Young (1908 – 1988) and colleagues\nHimsworth (England; early 1930s) insulin - sensitive forms of diabetes\nreported in 1938 that injections of anterior pituitary extract could Willy Gepts (Belgium, 1965) Suggested that insulitis caused β - cell\ninduce permanent diabetes in the dog, and that this was accom-\ndestruction (type 1 diabetes)\npanied by selective degranulation and loss of the β - cells [47] ; it Deborah Doniach and GianFranco Suggested that insulin - dependent\nwas surmised that these cells produced insulin, and this was Bottazzo (England, 1979) diabetes is an autoimmune disease\nfi nally confi rmed using immuno - histochemistry by Paul Lacy in Andrew Cudworth and John Insulin - dependent diabetes associated\n1959 [48] . Glucagon was similarly localized to the α - cells in 1962 Woodrow (England, 1975) with specifi c HLA antigens\nby John Baum and colleagues [49] . 14",
    "chunk_id": 111,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 889
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 36
    }
  },
  {
    "text": "--- Page 37 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\n(a) (b)\nFigure 1.15 Frederick Sanger (b . 1918) and Dorothy Hodgkin, n é e Crowfoot (1910 – 1994). Courtesy of Godfrey Argent Studio, London. The amino acid sequence of insulin was reported in 1955 by\nFrederick Sanger in Cambridge, UK [50] , and the three - dimen-\nsional structure of the molecule in 1969 by Dorothy Hodgkin, in\nOxford [51] ; both discoveries were recognized by the award of\nNobel Prizes (Figure 1.15 ). The complete insulin molecule was\nsynthesized from amino acids by Wang Ying - lai (1908 – 2001) and\ncolleagues in Shanghai in 1965 [52] . The insulin precursor, proin-\nsulin, was described in 1967 by Donald Steiner (b . 1930) in\nChicago [53] .",
    "chunk_id": 112,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 824
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 37
    }
  },
  {
    "text": "The fi rst bioassay for insulin, based on the hor-\nmone ’ s ability to lower blood glucose in the alloxan - diabetic rat,\nwas reported in 1950 by the Australian Joseph Bornstein (1918 –\n1994), working in London with Robin D. Lawrence (see Fig. 1.20 )\n[54] . This method was superseded in 1956 by Rosalyn Yalow and\nSolomon Berson in the USA, who discovered that insulin was\nFigure 1.16 Solomon Berson and Rosalyn Yalow. antigenic; they exploited the binding of the hormone to anti -\ninsulin antibodies to develop the fi rst radio - immunoassay [55] . This assay method revolutionized endocrinology – and indeed,\nmany areas of physiology and medicine – and was also rewarded glucose transporter (GLUT) proteins by Mueckler and colleagues\nwith a Nobel Prize (Figure 1.16 ). in the USA [62] . The sequence of rat insulin genes was described in 1977 by Axel\nUllrich ( b. 1945) and colleagues [56] , and the human sequence Management of d iabetes\nby Graham Bell ( b. 1948) and his group in 1980 [57] .",
    "chunk_id": 113,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 995
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 37
    }
  },
  {
    "text": "The exist- An objective observer surveying clinical diabetes during the half -\nence of insulin receptors was inferred from the insulin - binding century after the discovery of insulin and the “ resurrection ” (a\ncharacteristics of liver - cell membranes by Pierre Freychet ( b. word used by Joslin) of young people with diabetes would have\n1935) and colleagues in 1971 [58] , and the receptor protein was been dismayed by what he saw (Table 1.4 ). In particular, young\nisolated by Pedro Cuatrecasas ( b. 1936) in the following year [59] . people were dying of complications that had previously been\nThe gene encoding the insulin receptor was cloned and sequenced assumed to be the preserve of the elderly. Two particularly\nin 1985 by two groups [60,61] . In recent years, numerous depressing papers were published in 1947 and 1950. First, Henry\nadvances have helped to clarify how insulin exerts its biologic Dolger (1909 – 1997) in New York described 20 patients who ful-\nactions.",
    "chunk_id": 114,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 981
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 37
    }
  },
  {
    "text": "Among these was the discovery in 1985 of the fi rst of the fi lled the then - accepted criteria for excellent diabetic control, but\n15",
    "chunk_id": 115,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 134
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 37
    }
  },
  {
    "text": "--- Page 38 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nTable 1.4 Selected milestones in the management of diabetes. Lifestyle modifi cation\nLi Hsuan (China, 7th century) A void wine, sex and salty cereals\nThomas Willis (England, 17th century) Food restriction\nJohn Rollo (England, 1797) Animal diet\nApollinaire Bouchardat (France, 1875) Food restriction and increased exercise\nCarl von Noorden (Germany, 1903) “ Oatmeal ” cure\nFrederick Allen (USA, 1913) Starvation diet for early - onset diabetes\nKarl Petr é n (Sweden, 1915) High - fat, low - carbohydrate diet\nInsulin treatment\nGeorg Zuelzer (Germany, 1907) and Nicolas Paulesco (Romania, 1921) Isolated pancreatic extracts with hypoglycemic activity\nFrederick Banting, Charles Best, J.J.R.",
    "chunk_id": 116,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 862
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 38
    }
  },
  {
    "text": "Macleod, and James Collip Isolation and fi rst clinical use of insulin\n(Canada, 1922 – 1923)\nHans Christian Hagedorn (Denmark, 1936) Protamine insulin, the fi rst long - acting insulin\nDavid Goeddel (USA, 1979) Synthetic human - sequence insulin produced by recombinant DNA technology\nJohn Pickup (London, 1978) D escribed continuous subcutaneous insulin infusion\nJohn Ireland (Scotland, 1981) Invented pen injection device\nOral hypoglycemic agents\nAvicenna (Arabia, 10th century) Recommended lupin, fenugreek and zedoary seeds\nWillhelm Ebstein (Germany, 1876) Recommended sodium salicylate\nE. Frank (Germany, 1926) B iguanide derivative (Synthalin) introduced, but withdrawn because of toxicity\nCelestino Ruiz (Argentina, 1930) Noted hypoglycemic action of some sulfonamides\nAuguste Loubati è res (France, 1942) Discovered hypoglycemic action of prototype sulfonylurea\nH. Franke and J. Fuchs (Germany, 1955) Carbutamide introduced\nG.",
    "chunk_id": 117,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 934
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 38
    }
  },
  {
    "text": "Ungar (USA, 1957) Phenformin introduced\nDiabetic monitoring and treatment targets\nUniversity Group Diabetes Program (USA, 1969) F irst randomized trial in diabetes\nPeter S ö nksen and Robert Tattersall (1978) I ntroduction of home blood glucose monitoring\nR. Fl ü ckiger and K.H.",
    "chunk_id": 118,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 279
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 38
    }
  },
  {
    "text": "Winterhalter (Germany, 1975) Showed that HbA was glycated hemoglobin\n1c\nWorld Health Organization (1991) S t Vincent Declaration identifi ed targets for diabetes care\nDiabetes Control and Complications Trial (USA, 1993) P roved that improved glycemic control prevents and slows progression of\nmicrovascular complication in type 1 diabetes\nUK Prospective Diabetes Study (UK, 1998) P roved that improved glycemic and blood - pressure control improve microvascular and\nmacrovascular outcomes in type 2 diabetes\nManagement of complications\nGerd Meyer - Schwickerath (Germany, 1964) U se of xenon arc lamp to treat diabetic retinopathy\nUniversity of Minnesota Team (USA, 1966) First combined kidney – pancreas transplants\nCarl - Erik Mogensen and Hans - Henrik Parving (Denmark, 1980s) S trict blood pressure controls slows progression of diabetic neuropathy\nwho all developed severe retinopathy after 6 – 22 years [63] ; These and other studies raised questions about whether lower-\namong these was the fi rst patient ever to receive insulin at Mount ing blood glucose levels to normal could prevent diabetic com-\nSinai Hospital, New York, who also had heavy albuminuria and plications or reverse them once they had appeared.",
    "chunk_id": 119,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 1221
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 38
    }
  },
  {
    "text": "The hypothesis\nhypertension by the age of 32. Second, Ruth Reuting reported a remained untestable for four more decades, until the means to\ncohort of 50 young patients originally identifi ed in 1929 [64] . By achieve tight glycemic control and measure it had been devised. 1949, one - third had died (mostly from cardiovascular and renal\ndisease) at an average age of 25 years, after only 18 years of dia- Insulin\nbetes, and the survivors showed “ ominous signs of hypertension, For the fi rst decade after its discovery, insulin was available only\nazotemia and proteinuria in signifi cant numbers. ” This had in its soluble (regular) formulation, whose short - action profi le\noccurred despite the introduction of more versatile insulin prepa- required multiple daily injections.",
    "chunk_id": 120,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 780
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 38
    }
  },
  {
    "text": "The fi rst delayed - action prepa-\nrations (see below); the situation was so hopeless that it inaugu- ration, protamine insulinate, was introduced in 1936 by Hans\nrated 20 years of treatment with “ heroic ” measures such as Christian Hagedorn in Denmark (Figure 1.17 ) [65] . This was\nadrenalectomy and hypophysectomy. followed by protamine zinc insulin later the same year, then\n16",
    "chunk_id": 121,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 382
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 38
    }
  },
  {
    "text": "--- Page 39 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\ninsulin that can be given without injection. The fi rst inhaled\ninsulin was marketed in 2006 but withdrawn a year later because\nof lack of demand and concerns about safety [69] . Oral h ypoglycemic a gents\nThe fi rst orally active glucose - lowering drug, synthalin, a guani-\ndine derivative, was developed by Frank and colleagues in Breslau\nin 1926 [70] , but had to be withdrawn because of toxicity (a recur-\nrent problem for oral hypoglycemic drugs). The sulfonylureas\noriginated from the work of Auguste Loubati è res (1912 – 1977) in\nFrance during the early 1940s on the glucose - lowering action of a\nsulfonamide derivative, 2254RP. Loubati è res made the crucial\nobservations that proved that these drugs act as insulin secretago-\ngues and that they were effective in intact, but not in pancreatec-\ntomized, animals [71] .",
    "chunk_id": 122,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 989
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 39
    }
  },
  {
    "text": "In 1955 carbutamide was the fi rst\nsulfonylurea to enter clinical practice and tolbutamide followed\nin 1957. Phenformin, the fi rst biguanide, was introduced in 1959\nfollowing research into the metabolic effects of guanidine deriva-\nFigure 1.17 Hans Christian Hagedorn (1888 – 1971) from the Hagedorn Medal. tives which had built on Frank ’ s initial studies [72] . Metformin\nCourtesy of C. Binder, Steno Institute, Hvidovre, Denmark. appeared on the European market in 1960 but was not marketed\nin the USA until 1994. Troglitazone, the fi rst of a new class of\nglobin insulin in 1939, NPH (neutral protamine Hagedorn, or antidiabetic drugs, the glitazones, was also marketed in 1994 but\nisophane) in 1946, and the lente series in 1952. Long - acting insu- withdrawn because of liver damage. It was followed by rosiglita-\nlins were welcomed by diabetes specialists and patients, but their zone and pioglitazone.",
    "chunk_id": 123,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 911
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 39
    }
  },
  {
    "text": "Another new class of drugs, acting on the\nuse as a single daily injection probably produced worse glycemic incretin system, were introduced in 2005. These are either gluca-\ncontrol than three or four injections of soluble insulin. Indeed, gon - like peptide 1 (GLP - 1) agonists (such as exenatide) or inhibi-\ndelayed - action preparations were initially condemned by some tors of the enzyme dipeptidylpeptidase - 4 (DPP - 4) which breaks\ndiabetes specialists, such as Russell Wilder of the Mayo Clinic, down GLP - 1 (gliptins). because the patient could slip without apparent warning into Tolbutamide, phenformin and insulin were compared in the\nhypoglycemia. treatment of maturity - onset diabetes in the fi rst randomized con-\nThe number and variety of insulin preparations proliferated, trolled trial, the University Group Diabetes Program [ 73– 7 5].",
    "chunk_id": 124,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 855
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 39
    }
  },
  {
    "text": "but the main advances were in methods to produce highly puri- This much - criticized study concluded that the death rate was\nfi ed preparations from porcine or bovine pancreas, which higher for both oral agents than for placebo, and that insulin\nremained the source for therapeutic insulin until the early 1980s. (whether given in a fi xed or variable dose) was no better than\nInsulin was the fi rst therapeutic protein to be produced by placebo [75] . These fi ndings were interpreted by some as suggest-\nrecombinant DNA technology, initially by David Goeddel ( b. ing that treatment of maturity - onset diabetes was a waste of time\n1951), who expressed synthetic genes encoding the A - and – a myth that was only laid fi nally to rest by the UK Prospective\nB - chains separately in E scherichia coli and then combined these Diabetes Study. chemically to produce human - sequence insulin [66] .",
    "chunk_id": 125,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 895
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 39
    }
  },
  {
    "text": "From there,\ngenetic engineering has been used to produce “ designer ” insulins Glucose c ontrol and t reatment t argets\nsuch as the fast - acting insulin analogs lispro and aspart and the D uring the 1920s, opinion leaders advocated normalizing blood\n“ peakless ” basal insulins such as glargine and detemir. How much glucose in young patients with diabetes, the rationale being to\nthese will improve glycemic control in the generality of people “ rest ” the pancreas, in the hope that it might regenerate. The only\nwith diabetes is debatable; weekend golfers do not become cham- way of monitoring diabetic control was by testing the urine for\npions when given expensive clubs! glucose, and attempts to keep the urine free from sugar inevitably\nM ost people with diabetes still inject insulin subcutaneously. resulted in severe hypoglycemia and often psychologic damage.",
    "chunk_id": 126,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 870
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 39
    }
  },
  {
    "text": "From the patient ’ s viewpoint, major milestones were the replace- This led to the so- c alled “ f ree diet” movement – linked particu-\nment of glass and steel syringes by disposable plastic syringes with larly with Adolf Lichtenstein (Stockholm) and Edward Tolstoi\nfi ne - gauge needles, and then by “ pen ” injection devices invented (New York) – which encouraged patients to eat whatever they\nby John Ireland (1933 – 1988) in Glasgow, Scotland, in 1981 [67] . liked and not to worry about glycosuria, however heavy. Tolstoi ’ s\nPortable insulin infusion pumps were developed by John Pickup view [76] was that a life saved by insulin should be worth living,\n( b. 1947) and colleagues in London during the late 1970s [68] , and that patients should be able to forget that they had diabetes\nand have become progressively smaller and more sophisticated.",
    "chunk_id": 127,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 852
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 39
    }
  },
  {
    "text": "after each morning ’ s injection; it seems likely that many physi-\nPatients and manufacturers hope that there will eventually be an cians followed this policy for the next 40 years. 17",
    "chunk_id": 128,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 184
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 39
    }
  },
  {
    "text": "--- Page 40 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nAdult physicians were similarly ambivalent about the impor-\ntance of good glycemic control. Only one - third of diabetes physi-\ncians questioned in England in 1953 thought that normoglycemia\nwould prevent diabetic complications, and only one - half advised\nurine testing at home [77] . Practical monitoring of diabetic control became feasible in the\nlate 1970s with the introduction into clinical practice of test strips\nfor measuring blood glucose in a fi ngerprick sample and the\ndemonstration that ordinary patients could use them at home\n[78,79] . The discovery of hemoglobin A by Samuel Rahbar ( b . 1c\n1929) paved the way for glycated hemoglobin (HbA ) assays\n1c\nwhich gave an objective measure of overall glucose control [ 80].",
    "chunk_id": 129,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 908
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 40
    }
  },
  {
    "text": "These methods in turn made possible the North American\nDiabetes Control and Complications Trial, which in 1993 fi nally\nestablished that good control prevents and delays the progression\nof microvascular complications in type 1 diabetes [ 81]. For type\n2 diabetes, the importance of good glycemic control was defi ni-\ntively proved by another landmark study, the UK Prospective\nDiabetes Study (UKPDS), masterminded in Oxford, UK, by\nRobert Turner (Figure 1.18 ). The UKPDS reported in 1998, and\nnot only showed a benefi cial effect of improved glycemic control\non microvascular complications [82] , but also established the\nimportance of treating hypertension [83] . By the late 1990s it was\nclear that reducing glucose levels, high blood pressure or choles-\nterol separately would reduce the frequency of heart disease and\ndeath and it was natural to wonder whether tackling them simul-\ntaneously (multiple risk factor intervention) would be even\nbetter.",
    "chunk_id": 130,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 954
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 40
    }
  },
  {
    "text": "The Steno 2 study, which began in Denmark in 1992,\nenrolled patients with type 2 diabetes with microalbuminuria and\nafter 13 years of follow - up showed that multiple risk factor inter-\nvention reduced the risk of death by 20% and the risk of develop-\ning nephropathy, retinopathy and neuropathy by 50% [84] . Figure 1.18 Robert Turner (1939 – 1999), instigator of the UKPDS, the fi rst\nstudy to show that good control of blood glucose and blood pressure was\nbenefi cial in type 2 diabetes. Courtesy of the British Diabetic Association. Diabetic c omplications\nApart from the general benefi ts of controlling blood glucose,\nsome specifi c treatments have emerged for certain chronic com-\nplications.",
    "chunk_id": 131,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 699
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 40
    }
  },
  {
    "text": "Well - conducted clinical trials during the late 1970s Diabetic k etoacidosis\nshowed the effectiveness of laser photocoagulation in preventing The introduction of insulin was only one aspect of the manage-\nvisual loss from both maculopathy and proliferative retinopathy ment of this acute and previously fatal complication of diabetes. [85] . This technique was derived from the xenon arc lamp origi- Of the fi rst 33 cases treated by Joslin and his colleagues between\nnally described in the late 1950s by Gerd Meyer - Schwickerath January 1, 1923 and April 1, 1925, 31 survived – an excellent\n(1921– 9 2) of Essen, Germany [ 86].",
    "chunk_id": 132,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 630
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 40
    }
  },
  {
    "text": "outcome, even by modern standards, which Joslin [89] attributed\nT he importance of blood pressure control in preventing the to: “ Promptly applied medical care, rest in bed, special nursing\nprogression of nephropathy is now fully recognized, and angi- attendance, warmth, evacuation of the bowels by enema, the\notensin - converting enzyme inhibitors may be particularly introduction of liquids into the body, lavage of the stomach,\nbenefi cial; that blood pressure control slowed the progression of cardiac stimulants, and above all the exclusion of alkalis. ”\nnephropathy was shown in studies by Carl - Erik Mogensen Sadly, other centers did not pay so much attention to detail. In\n( b. 1938) and Hans - Henrik Parving (b . 1943) published in the 1933, the death rate from ketoacidosis in Boston was only 5%,\nearly 1980s [87] .",
    "chunk_id": 133,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 828
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 40
    }
  },
  {
    "text": "The measurement of low albumin concentra- but elsewhere in North America and Europe it averaged 30% and\ntions in urine (microalbuminuria), now used throughout the could be as high as 75%. An important advance in management\nworld to screen for and monitor the course of diabetic neph- was the acceptance of relatively low - dose insulin replacement,\nropathy, is derived from a radioimmunoassay developed in 1969 following the example of Ruth Menzel and colleagues in\nby Harry Keen and Costas Chlouverakis, at Guy ’ s Hospital in Karlsburg, Germany [90] . This broke with the tradition of high -\nLondon [88] . dose regimens such as that proposed by Howard Root in the USA,\n18",
    "chunk_id": 134,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 673
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 40
    }
  },
  {
    "text": "--- Page 41 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\nwhich had recommended an average of 1200 U insulin during the provided by an experienced and dedicated team consisting of a\nfi rst 24 hours of treatment [91] . Another step forward was the physician, obstetrician and pediatrician [94] . Pedersen ’ s target of\nrecognition by Jacob Holler in 1946 of the danger of hypokalemia a fetal mortality rate of 6% was not achieved in most European\n[92] . Holler ’ s observation helped to establish the need for moni- or US units until the 1980s. toring plasma potassium levels, which became feasible with the\nintroduction of the fl ame photometer, and replacing potassium Delivery of c are for p eople with d iabetes\naccordingly.",
    "chunk_id": 135,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 829
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 41
    }
  },
  {
    "text": "From the earliest days of insulin injection and urine testing, it\nwas apparent that people with diabetes needed knowledge and\nD iabetic p r egnancy practical skills to manage their disease effectively. Lip- s ervice was\nAs late as 1950, the outcome of pregnancy in women with diabe- often paid to the importance of diabetes education, but most\ntes was still very poor in most units, with perinatal fetal losses of patients were badly informed. In 1952, Samuel Beaser (1910 –\n45 – 65%, some 10 times higher than in the general population. 2005) questioned 128 patients attending the Boston Diabetes\nExceptions to this depressing rule were the units run by Priscilla Fair, and found that “ all were distinctly defi cient in knowledge of\nWhite at the Joslin Clinic in Boston, who had published excellent their disease ” [95] ; he felt that responsibility lay with both doctors\nresults as early as 1935 [93] , and by J ø rgen Pedersen in and administrators.",
    "chunk_id": 136,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 953
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 41
    }
  },
  {
    "text": "Further studies during the 1960s by Donnell\nCopenhagen (Figure 1.19 ). Pedersen identifi ed the common Etzwiler (1927 – 2003) in Minneapolis showed that many doctors\nfeatures underpinning success as good diabetic control and care and nurses were also ignorant about managing diabetes. Since the\n(a) (b)\nFigure 1.19 J ø rgen Pedersen (1914 – 1978) and Ivo Drury (1905– 1 988), pioneers, with Priscilla White (1900 – 1989), in the management of pregnancy in women with\ntype 1 diabetes. Courtesy of Dr. Carl Erik Mogensen and the Royal College of Physicians of Ireland. 19",
    "chunk_id": 137,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 569
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 41
    }
  },
  {
    "text": "--- Page 42 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\n(a) (b)\nFigure 1.20 Ernesto Roma (1887 – 1978) and (right) Robin D. Lawrence (1892– 1968). Photograph of Dr. Roma by courtesy of Manuel Machado S á Marques and the\nAssocia ç ã o Protectura das Diab é ticos de Portugal. 1980s, diabetes specialist nurses and nurse educators have been jointly in 1990 by the EASD and the World Health Organization\nappointed in increasingly large numbers – thus fulfi lling a sug- [96] . gestion originally made by Joslin in 1916. National and international diabetes associations have also\nReferences\nplayed an important part by supporting scientifi c and clinical\nresearch, providing practical and moral help for patients, and\n1 Willis T . Pharmaceutice Rationalis; sive, Diatriba de Medicamentorum\nlobbying governments on patients ’ behalf.",
    "chunk_id": 138,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 946
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 42
    }
  },
  {
    "text": "The fi rst of these\nOperationibus in Humano Corpore [2 parts in 1 vol]. Oxford :\norganizations was the Portuguese Association for the Protection\nSheldonian Theatre , 1674 . of Poor Diabetics, founded in 1926 by Ernesto Roma of Lisbon\n2 Dobson M . Experiments and observations on the urine in diabetes . after an inspiring visit to Joslin ’ s clinic in Boston (Figure 1.20 ). Med Obs Inq 1776 ; 5 : 298 – 316 . The Association ’ s aim was to provide free insulin and education\n3 Rollo J . A n Account of Two Cases of the Diabetes Mellitus, With\nfor people with diabetes and their families. In the UK, the Diabetic Remarks as They Arose During the Progress of the Cure . London : C. Association (later the British Diabetic Association, and now Dilly , 1797 . [A 2nd edition with more cases was published in 1798\nDiabetes UK) was established in 1934 by Robin Lawrence of and a 3rd edition in 1806.]\nKing ’ s College Hospital, London, helped by the novelist H.G. 4 Chevreul ME .",
    "chunk_id": 139,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 974
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 42
    }
  },
  {
    "text": "Note sur le sucre du diab è te . A nn Chim (Paris) 1815 ;\nWells (Figure 1.20 ). Similar organizations were later founded in 95 : 319 – 320 . France (1938), the USA (1940) and Belgium (1942), and now 5 Olmsted JMD . Claude Bernard, 1813 – 79 . D iabetes 1953 ; 2 : 162 – 164 . 6 Bernard C . Chiens rendus diab é tiques . C R Seances Soc Biol (Paris)\nexist in most countries. 1850 ; 1 : 60 . On a wider scale, the International Diabetes Foundation\n7 Macleod JJR . Recent work on the pathologic physiology of glycosuria . was established in 1950 and the European Association for the\nJAMA 1914 ; 1 13 : 1226 – 1235 . Study of Diabetes (EASD) in 1964. These organizations are\n8 Von Mering J , Minkowski O . Diabetes mellitus nach Pank rea-\ndevoted to the practice of diabetes care as well as the basic and\nsextirpation . Arch Exp Pathol Pharmacol Leipzig 1890 ; 2 6 : 371 – 387 . clinical science of the disease, and have been valuable in coordi- 9 Tattersall RB .",
    "chunk_id": 140,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 959
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 42
    }
  },
  {
    "text": "Charles - É douard Brown - S é quard: double hyphenated\nnating treatment targets and strategies at international level; neurologist and forgotten father of endocrinology . D iabet Med 1994 ;\nan important example was the St. Vincent Declaration, issued 11 : 728 – 731 . 20",
    "chunk_id": 141,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 271
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 42
    }
  },
  {
    "text": "--- Page 43 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\n10 Laguesse GE . Sur la formation des î lots de Langerhans dans le pan- 36 Feutren G , Papoz L , Assan R , Vialettes B , Karsenty G , Vexiau P , e t al . cr é as . C R S é ances Mem Soc Biol 1893 ; 4 5 : 819 – 820 . Cyclosporin increases the rate and length of remissions in insulin -\n11 Langerhans P . Beitr ä ge zur mikroskopischen Anatomie der dependent diabetes of recent onset: results of a multicentre double -\nBauchspeicheldr ü se [dissertation]. Berlin : Gustave Lange , 1869 . blind trial . L ancet 1986 ; 2 : 119 – 124 . 12 De Meyer J . Sur la signifi cation physiologique de la s é cr é tion interne 37 Gale EA , Bingley PJ , Emmett CL , Collier T , European Nicotinamide\ndu pancr é as . Z entralbl Physiol 1904 ; 18 :S 826 . Diabetes Intervention Trial (ENDIT) Group. E uropean Nicotinamide\n13 Saundby R .",
    "chunk_id": 142,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 977
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "The Bradshaw Lecture on the morbid anatomy of diabetes Diabetes Intervention Trial (ENDIT): a randomised controlled trial\nmellitus . Lancet 1890 ; i i : 381 – 386 . of intervention before the onset of type 1 diabetes . Lancet 2004 ;\n14 Jaeger E . Jaeger ’ s Atlas of Diseases of the Ocular Fundus: with New 363 : 925 – 931 . Descriptions, Revisions, and Additions , tr. and ed. Albert DM. 38 Diabetes Prevention Trial – Type 1 Diabetes Study Group . Effects of\n[Translation of Ophthalmoskopischer Hand- A tlas, rev. ed. Salzmann insulin in relatives of patients with type 1 diabetes mellitus . N Engl J\nM., Leipzig, 1890; 1st edn. 1869.] Philadelphia : Saunders , 1972 . Med 2002 ; 346 : 1685 – 1691 . 15 Nettleship E . Haemorrhagic retinitis in a patient with diabetes, vari- 39 Ryan EA , Paty BW , Senior PA , Bigam D , Alfadhli E , Kneteman NM ,\ncose swellings on a retinal vein in the right eye. Trans Opthalmol Soc et al . Five - year follow - up after clinical islet transplantation .",
    "chunk_id": 143,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 990
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "Diabetes\nUK 1888 ; 8 : 161 . 2005 ; 5 4 : 2060 – 2069 . 16 Hirschberg J . Ü ber diabetische Netzhautentz ü ndung . Dtsch Med 40 Wagener HF , Dry TJS , Wilder RM . Retinitis in diabetes . N Engl J Med\nWochenschr 1890 ; 1 6 : 1181 . 1934 ; 2 11 : 1131 – 1137 . 17 Pavy FW . Introductory address to the discussion on the clinical aspect 41 Kimmelstiel P , Wilson C . Intercapillary lesions in the glomeruli of the\nof glycosuria . L ancet 1885 ; i i : 1085 – 1087 . kidney . Am J Pathol 1936 ; 12 : 83 – 97 . 18 Pavy FW . On diabetic neuritis . Lancet 1904 ; i i : 17 – 19 . 42 Bloodworth JMB . A re - evaluation of diabetic glomerulosclerosis 50\n19 Griesinger W . Studien ü ber Diabetes . A rch Physiol Heilkd 1859 ; years after the discovery of insulin . Hum Pathol 1978 ; 9 : 439 – 453 . 3 : 1 – 75 . 43 Lundb æ k K . Long - Term Diabetes: the Clinical Picture in Diabetes\n20 Lanceraux E .",
    "chunk_id": 144,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 888
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "Le diab è te maigre: ses symptomes, son é volution, son Mellitus of 15 – 25 Years ’ Duration with a Follow Up of a Regional Series\npronostic et son traitement . Union M é d Paris 1880 ; 2 0 : 205 – 211 . of Cases . London : Lange, Maxwell and Springer , 1953 . 21 Joslin EP . Present - day treatment and prognosis in diabetes . A m J Med 44 Lundb æ k K . Diabetic angiopathy: a specifi c vascular disease . L ancet\nSci 1915 ; 150 : 485 – 496 . 1954 ; i : 377 – 379 . 22 Joslin EP . T he Treatment of Diabetes Mellitus: with Observations Based 45 Kinoshita JH . Mechanisms initiating cataract formation . Invest\nupon One Thousand Cases . Philadelphia : Lea & Febiger , 1916 . Ophthalmol 1974 ; 1 3 : 713 – 724 . 23 Zuelzer GL . Experimentelle Untersuchungen ü ber den Diabetes . 46 Lane MA . The cytological characters of the areas of Langerhans . Am\nBerlin Klin Wochenschr 1907 ; 4 4 : 474 – 475 . J Anat 1907 ; 7 : 409 – 421 . 24 Richards DW .",
    "chunk_id": 145,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 944
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "The effect of pancreas extract on depancreatized 47 Young FG . Permanent experimental diabetes produced by pituitary\ndogs: Ernest L. Scott ’ s thesis of 1911 . Perspect Biol Med 1966 ; 10 : (anterior lobe) injections . Lancet 1937 ; i i : 372 – 374 . 84 – 95 . 4 8 L acy P E. E lectron microscopic and fl uorescent antibody studies on\n25 Paulesco NC . Recherche sur le r ô le du pancr é as dans l ’ assimilation islets of Langerhans . Exp Cell Res 1959 ; 7 : 296 – 308 . nutritive . Arch Int Physiol 1921 ; 17 : 85 – 109 . 49 Baum J , Simmons BE , Unger RH , Madison LL . Localization of glu-\n26 Bliss M . T he Discovery of Insulin . Chicago : University of Chicago cagon in the A - cells in the pancreatic islet by immunofl uorescence . Press , 1982 . Diabetes 1962 ; 1 1 : 371 – 378 . 27 Banting FG , Best CH , Collip JB , Campbell WR , Fletcher AA . 50 Brown H , Sanger F , Kitai R . The structure of pig and sheep insulin .",
    "chunk_id": 146,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 927
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "Pancreatic extracts in the treatment of diabetes mellitus: preliminary Biochem J 1955 ; 6 0 : 556 – 565 . report . C an Med Assoc J 1922 ; 1 2 : 141 – 146 . 51 Adams MJ , Blundell TL , Dodson EJ , Hodgkin DC . Structure of 2 zinc\n28 Hetenyi G . The day after: how insulin was received by the medical insulin crystals. Nature 1969 ; 224 : 491 – 495 . profession . Perspect Biol Med 1995 ; 3 8 : 396 – 405 . 52 Kung K , Huang W , et al. Total synthesis of crystalline insulin . Sci\n29 Falta W . D ie Zuckerkrankheit . Berlin : Urban und Schwarzenberg , Sinica 1966 ; 1 5 : 544 – 561 . 1936 . 53 Steiner DF , Oyer PE . The biosynthesis of insulin and probable precur-\n30 Himsworth HP . Diabetes mellitus: its differentiation into insulinsen- sor of insulin by a human islet cell adenoma . Proc Natl Acad Sci U S\nsitive and insulin - insensitive types . L ancet 1936 ; i : 127 – 30 . A 1967 ; 57 : 473 – 480 . 31 DeFronzo RA , Tobin JD , Andres R .",
    "chunk_id": 147,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 944
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "Glucose clamp technique: a 54 Bornstein J , Lawrence RD . Two types of diabetes, with and without\nmethod for quantifying insulin secretion and resistance . Am J Physiol available plasma insulin . B r Med J 1951 ; i : 732 – 735 . 1979 ; 2 37 :E 214 – E 223 . 55 Yalow RS , Berson SA . Assay of plasma insulin in human subjects by\n32 Tattersall RB . Mild familial diabetes with dominant inheritance . Q J immunological methods . Nature 1958 ; 184 : 1648 – 1649 . Med 1974 ; 4 3 : 339 – 357 . 56 Ullrich A , Shrine J , Chirgwin J , Pictet R , Tischer E , Rutter WJ , e t al. 33 Opie EL . On the relation of chronic interstitial pancreatitis to the Rat insulin genes: construction of plasmids containing the coding\nislands of Langerhans and to diabetes mellitus . J Exp Med 1901 ; sequences . S cience 1977 ; 196 : 1313 – 1319 . 5 : 393 – 397 . 57 Bell GI , Pictet RL , Rutter WJ , Cordell B , Tischer E , Goodman HM . 34 Gepts W . Pathologic anatomy of the pancreas in juvenile diabetes .",
    "chunk_id": 148,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 985
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "Sequence of the human insulin gene . N ature 1980 ; 284 : 26 – 32 . Diabetes 1965 ; 1 4 : 619 – 633 . 58 Freychet P , Roth J , Neville DM Jr . Insulin receptors in the liver: spe-\n35 Bottazzo GF , Florin - Christensen A , Doniach D . Islet - cell antibodies cifi c binding of [ 125 I] insulin of the plasma membrane and its relation\nin diabetes mellitus with autoimmune polyendocrine defi ciencies . to insulin bioactivity. Proc Natl Acad Sci U S A 1971 ; 6 8 : 1833 –\nLancet 1974 ; i i : 1279 – 1283 . 1837 . 21",
    "chunk_id": 149,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 512
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 43
    }
  },
  {
    "text": "--- Page 44 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\n59 Cuatrecasas P . Affi nity chromatography and purifi cation of the 82 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood -\ninsulin receptor of liver cell membrane . P roc Natl Acad Sci U S A 1972 ; glucose control with sulphonylureas or insulin compared with con-\n62 : 1277 – 1281 . ventional treatment and risk of complications in patients with type 2\n60 Ullrich A , Bell JR , Chen EY , Herrera R , Petruzzelli LM , Dull TJ , e t al. diabetes (UKPDS 33) . L ancet 1998 ; 3 52 : 837 – 853 . Human insulin receptor and its relationship to the tyrosine kinase 83 UK Prospective Diabetes Study (UKPDS) Group . Tight blood pres-\nfamily of oncogenes . N ature 1985 ; 3 13 : 756 – 761 .",
    "chunk_id": 150,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 867
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "sure control and risk of macrovascular and microvascular complica-\n61 Ebina Y , Ellis L , Jarnagin K , Edery M , Graf L , Clauser E , et al. The tions in type 2 diabetes: UKPDS 38 . B r Med J 1998 ; 3 17 : 703 – 713 . human insulin receptor cDNA: the structural basis for hormone - 84 Gaede P , Vedel P , Larsen N , Jensen GV , Parving HH , Pedersen O . activated transmembrane signalling . Cell 1985 ; 40 : 747 – 758 . Multifactorial intervention and cardiovascular disease in type 2 dia-\n62 Mueckler M , Caruso C , Baldwin SA , Panico M , Blench I , Morris HR , betes . N Engl J Med 2003 ; 3 48 : 383 – 393 . et al. Sequence and structure of a human glucose transporter . Science 85 Diabetic Retinopathy Research Group . Photocoagulation treatment\n1985 ; 229 : 941 – 945 . of proliferative diabetic retinopathy. The second report of Diabetic\n63 Dolger H . Clinical evaluation of vascular damage in diabetes mellitus . Retinopathy Study Findings . O phthalmology 1978 ; 8 5 : 82 – 106 .",
    "chunk_id": 151,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 987
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "JAMA 1947 ; 134 : 1289 – 1291 . 86 Meyer - Schwickerath G . L ight Coagulation (Drance SM, trans). St\n64 Reuting RE . Progress notes on fi fty diabetic patients followed 25 or Louis : Mosby , 1960 . more years . A rch Intern Med 1950 ; 8 6 : 891 – 897 . 87 Mogensen CE . Long - term antihypertensive treatment inhibiting pro-\n65 Deckert T . H.C. Hagedorn and Danish Insulin . Herning, Denmark : gression of diabetic nephropathy . Br Med J 1982 ; 2 85 : 685 – 688 . Kristensen , 2000 . 88 Keen H , Chlouverakis C . An immunoassay for urinary albumin at low\n66 Goeddel DV , Kleid DG , Bolivar F . E xpression in Escherichia coli of concentrations . L ancet 1963 ; i i : 913 – 916 . chemically synthesized genes from human insulin . P roc Natl Acad Sci 89 Joslin EP , Root HF , White P . Diabetic coma and its treatment . Med\nU S A 1979 ; 76 : 106 – 110 . Clin North Am 1925 ; 8 : 1873 – 1919 . 67 Paton JS , Wilson M , Ireland JT , Reith SBM . Convenient pocket 90 Menzel R , Zander E , Jutzi E .",
    "chunk_id": 152,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 994
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "Treatment of diabetic coma with low -\ninsulin syringe . L ancet 1981 ; i : 189 – 190 . dose injections of insulin . Endokrinologie 1976 ; 6 7 : 230 – 239 . 68 Pickup JC , Keen H , Parsons JA , Alberti KGMM . Continuous subcu- 91 Root HF . The use of insulin and the abuse of glucose in treatment of\ntaneous insulin infusion: an approach to achieving normoglycaemia . diabetic coma . JAMA 1945 ; 1 27 : 557 – 563 . Br Med J 1978 ; i : 204 – 207 . 92 Holler JW . Potassium defi ciency occurring during the treatment of\n69 Mathieu C , Gale EAM . Inhaled insulin: gone with the wind? diabetic acidosis. JAMA 1946 ; 1 31 : 1186 – 1188 . Diabetologia 2008 ; 5 1 : 1 – 5 . 9 3 W hite P . P regnancy complicating diabetes. S urg Gynecol Obstet 1935 ;\n70 Frank E , Nothmann M , Wagner A . Ü ber synthetisch dargestellte 61 : 324 – 332 . K ö rper mit insulinartiger Wirkung auf den normalen und den dia- 9 4 P edersen J , B randstrup E . F oetal mortality in pregnant diabetics: strict\nbetischen Organismus .",
    "chunk_id": 153,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 998
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "Klin Wochenschr 1926 ; 2100 – 2107 . control of diabetes with conservative obstetric management . L ancet\n71 Loubati è res A . Th è se Doctorat Sciences Naturelles , no. 86. Montpellier, 1956 ; i : 607 – 610 . 1946. M ontpellier: C ausse, Graille et Castelnau, 1 956. 9 5 B easer S B. T eaching the diabetic patient. Diabetes 1956 ; 5 : 146 – 149 . 72 Tyberghein JM , Williams RH . Metabolic effects of phenylethyldigua- 9 6 A non. D iabetes care and research in Europe: the Saint Vincent\nnide, a new hypoglycemic compound (23386) . Proc Soc Exp Med Biol Declaration . D iabet Med 1990 ; 7 : 360 . 1957 ; 96 : 29 – 32 . 73 Tattersall RB . The quest for normoglycaemia: a historical perspective . Further r eading\nDiabet Med 1994 ; 1 1 : 618 – 635 . 74 Marks HM . The Progress of Experiment: Science and Therapeutic\nReform in the United States . New York : Cambridge University Press , Bliss M . T he Discovery of Insulin . Toronto : McClelland and Stewart , 1982;\n1997 : 197 – 228 .",
    "chunk_id": 154,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 982
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "and Edinburgh: Paul Harris Publishing, 1983 . 75 University Group Diabetes Program . A study of the effects of hypogly- Deckert , T . H C Hagedorn and Danish Insulin . Copenhagen : Poul\ncemic agents on vascular complications in patients with adult onset Kristensen , 2000 . diabetes . D iabetes 1970 ; 1 9 (Suppl.): 789 – 830 . Feudtner C . B itter Sweet, Diabetes, Insulin and the Transformation of\n76 Tolstoi E . The objective of modern diabetic care . Psychosom Med Illness . Chapel Hill and London : University of North Carolina Press ,\n1948 ; 10 : 291 – 294 . 2003 . 77 Walker GF . Refl ections on diabetes mellitus: answers to a question- Feudtner C , Gabbe S . Diabetes and pregnancy: four motifs of modern\nnaire . L ancet 1953 ; i i : 1329 – 1332 . medical history . Clin Obstet Gynecol 2000 ; 43 : 4 – 16 . 78 Sonksen P , Judd S , Lowy C . Home monitoring of blood glucose: Goldner MG . Historical review of oral substitutes for insulin . Diabetes\nmethod for improving diabetic control .",
    "chunk_id": 155,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 996
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "Lancet 1978 ; 1 : 729 – 732 . 1957 ; 6 : 259 – 262 . 79 Walford S , Gale EAM , Allison SP , Tattersall RB . Self - monitoring of Ionescu - Tirgoviste C . T he Rediscovery of Insulin . Bucharest : Geneze , 1996 . blood glucose: improvement of diabetic control . Lancet 1978 ; Loubati è res A . The hypoglycaemic sulphonamides: history and develop-\n1 : 732 – 735 . ment of the problem from 1942 to 1955 . A nn N Y Acad Sci 1957 ;\n80 Rahbar S . An abnormal hemoglobin in the red cells of diabetics . Clin 71 : 4 – 28 . Chim Acta 1968 ; 22 : 296 – 298 . Medvei VC . A History of Endocrinology. L ancaster: M TP Press, 1 982. 8 1 D iabetes Control and Complications Trial Research Group. T he effect Tattersall R . Diabetes: t he biography , Oxford : Oxford University Press ,\nof intensive treatment of diabetes on the development and progres- 2009 . sion of long - term complications in insulin - dependent diabetes mel- von Engelhardt , D . D iabetes: its Medical and Cultural History. B erlin:\nlitus .",
    "chunk_id": 156,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 999
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "N Engl J Med 1993 ; 3 29 : 977 – 986 . Springer , 1989 . 22",
    "chunk_id": 157,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 59
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 44
    }
  },
  {
    "text": "--- Page 45 ---\nChapter 1: The History of Diabetes Mellitus\nPart 1: Part 1 Diabetes in its Historical and Social Context\nHistory of Diabetes Mellitus Chapter 1\nWebsites Archives\nGeneral h istory of d iabetes The notebooks and personal papers of the discoverers of insulin are\nhttp://pr15.mphy.lu.se/Diahistory1.html preserved at the Thomas Fisher Rare Book Library, University of\nhttp://www.diabetes/living.com/basics/histdev.htm Toronto, Canada.\nDiscovery of i nsulin\nDiscovery of Insulin website: http://web.idirect.com/ ∼ discover\nBanting Digital Library: http://www.Newtecumseth.library.on.ca.\nbanting/main.html\nNobel Prize Website: http://www.nobel.se/medicine/laureates/1923\n23",
    "chunk_id": 158,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 683
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 1,
      "chapter_title": "The History of Diabetes Mellitus",
      "page_number": 45
    }
  },
  {
    "text": "--- Page 46 ---\nChapter 2: The Classifi cation and Diagnosis of Diabetes\nPart 1: Part 1 Diabetes in its Historical and Social Context\n2\nThe Classifi cation and Diagnosis of\nDiabetes Mellitus\nK. George M.M.",
    "chunk_id": 159,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 205
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 46
    }
  },
  {
    "text": "Alberti\nE ndocrinology and Metabolism, Imperial College St Mary ’ s Campus, London, UK\nKey points\n(cid:129) The classifi cation of diabetes mellitus is based on four main categories: individuals two abnormal values are required and an oral glucose\nType 1, Type 2, other specifi c types, and gestational diabetes mellitus tolerance test may be needed\n(cid:129) Impaired glucose tolerance and impaired fasting glycemia are high- r isk (cid:129) The diagnosis of diabetes can not be excluded by measuring fasting\nstates collectively termed “ intermediate hyperglycemia ” plasma glucose alone\n(cid:129) Type 2 diabetes is a diagnosis by exclusion and as more specifi c causes (cid:129) HbA has major advantages over glucose testing in terms of\n1c\nare found these will move out of the type two category into other convenience and lack of variability, although it is not adequately quality\nspecifi c types assured or standardized in many places, and is costly.",
    "chunk_id": 160,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 954
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 46
    }
  },
  {
    "text": "Nonetheless, it is\n(cid:129) Measurement of glucose continues to be the mainstay of diagnosis. In already recommended in some countries as an alternative diagnostic\nthe symptomatic person a single abnormal value, either casual or test. This is likely to become more widespread\nfasting, is often enough to confi rm the diagnosis. In asymptomatic\nwas generally stated that the latter was just a milder form of the\nIntroduction disease. Diagnosis now depended on glucose measurement with\nsome using glucose tolerance tests. There were no standard cri-\nDiabetes mellitus is a disease of antiquity (see Chapter 1 ). A treat- teria for these initially, although glucose levels were clearly above\nment was described in the Ebers papyrus and as long ago as 600 b c normal. Diagnosis usually occurred after clinical development of\ntwo main types were distinguished.",
    "chunk_id": 161,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 856
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 46
    }
  },
  {
    "text": "Perhaps the most famous the disease with the combination of symptoms with raised glucose\ndescription was by Arateus the Cappadocian who talked of the in the blood or glycosuria being diagnostic, together with ketonu-\nmelting down of fl esh into urine and of the end being speedy. ria in the juvenile - onset form. Over the ensuing centuries sporadic descriptions were noted, with A further breakthrough occurred with the work of Himsworth\nMaimonides in Egypt pointing out its relative rarity. It was attrib- in 1936. Himsworth ’ s work showed that people with diabetes\nuted to a salt - losing state although the sweetness of the urine had could be divided into insulin - resistant and insulin - sensitive types,\nlong been known. Undoubtedly, virtually all of these accounts with the former much more common in those with the maturity -\nreferred to type 1 (T1DM) or late type 2 diabetes (T2DM). o nset variety [ 1].",
    "chunk_id": 162,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 914
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 46
    }
  },
  {
    "text": "The next milestone was the development of the\nDiabetes was better recognized in the 17th and 18th centuries, radioimmunoassay for insulin which allowed the unequivocal\nwith the association with obesity noted in some cases. The demonstration of insulin defi ciency, or indeed absence, in those\nobvious breakthrough came in the 17th century with the demon- with juvenile - onset diabetes while levels were apparently normal\nstration of excess glucose in the urine and later also in blood. or raised in those with maturity - onset diabetes. The presence of excess ketones was shown in the 19th century. At that time, diabetes was still considered to be a relatively\nA clear description of the two main types of diabetes appeared at uncommon disorder occurring predominantly in Europids.",
    "chunk_id": 163,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 783
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 46
    }
  },
  {
    "text": "The\nthe end of the 19th century, with the distinction being made World Health Organization (WHO) began to take note and held\nbetween that occurring in young people with a short time course its fi rst Expert Committee meeting in 1964 [2] . The real break-\nbefore ketoacidosis supervened, and that found in older people through, however, in terms of diagnosis and classifi cation came\nwho were obese. Over the next decades these became known as in 1980 with the publication of the second Expert Committee\njuvenile - onset diabetes and maturity - onset diabetes, although it report [3] shortly after the report from the National Diabetes Data\nGroup (NDDG) in the USA in 1979 [4] . These events form the\nstarting point for the diagnostic criteria and classifi cation used\nTextbook of Diabetes, 4th edition. Edited by R. Holt, C. Cockram,\nA. Flyvbjerg and B. Goldstein. © 2010 Blackwell Publishing. today. 24",
    "chunk_id": 164,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 903
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 46
    }
  },
  {
    "text": "--- Page 47 ---\nChapter 2: The Classifi cation and Diagnosis of Diabetes\nPart 1: Part 1 Diabetes in its Historical and Social Context\nClassifi cation and Diagnosis of Diabetes Mellitus Chapter 2\nTable 2.1 Etiologic classifi cation of disorders of glycemia. Adapted from\nDefi nitions\nWorld Health Organization [6] . D iabetes mellitus is a metabolic disorder of multiple etiologies. It Type 1 diabetes (β - cell destruction)\nis characterized by chronic hyperglycemia together with distur- (cid:129) Autoimmune\nbances of carbohydrate, fat and protein metabolism resulting (cid:129) Idiopathic\nfrom defects of insulin secretion, insulin action or both [6] . The Type 2 diabetes (insulin resistance with insulin hyposecretion)\nrelative contribution of these varies between different types of Other specifi c types (Table 2.2 )\ndiabetes.",
    "chunk_id": 165,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 832
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 47
    }
  },
  {
    "text": "These are associated with the development of the spe- Gestational diabetes (includes former categories of gestational IGT and\ncifi c microvascular complications of retinopathy, which can lead gestational diabetes)\nto blindness, nephropathy with potential renal failure, and neu-\nIGT, impaired glucose tolerance. ropathy. The latter carries the risk of foot ulcers and amputation\nand also autonomic nerve dysfunction. Diabetes is also associated\nwith an increased risk of macrovascular disease. diabetes mellitus was also introduced in recognition of a different\nThe characteristic clinical presentation is with thirst, polyuria, phenotype found particularly in Asia and sub - Saharan Africa. blurring of vision and weight loss. This can lead to ketoacidosis Impaired glucose tolerance (IGT) was also introduced as a high\nor hyperosmolar non - ketotic coma (see Chapter 19 ). Often, risk class.",
    "chunk_id": 166,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 893
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 47
    }
  },
  {
    "text": "symptoms are mild or absent and mild hyperglycemia can persist Based on increasing knowledge, WHO revisited the classifi ca-\nfor years with tissue damage developing, although the person tion in 1999 [6] as did the American Diabetes Association (ADA)\nmay be totally asymptomatic. [7] . It was recognized that the terms IDDM and NIDDM, although\nsuperfi cially appealing, were often confusing and unhelpful – as\nin patients with insulin - treated T2DM. The new classifi cation\nClassifi cation attempted to encompass both etiology and clinical stages of the\ndisease as well as being useful clinically. This was based on the\nThere was awareness of different grades of severity of diabetes for suggestion of Kuzuya and Matsuda [8] . This acknowledges that\nmany centuries; however, the possibility that there were two diabetes may progress through several clinical stages (e.g. from\ndistinct types only emerged at the beginning of the 20th century.",
    "chunk_id": 167,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 941
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 47
    }
  },
  {
    "text": "normoglycemia to ketoacidosis) while having a single etiologic\nEven then there was no real clue to distinct etiologies. In the process such as autoimmune attack on the β - cells. Similarly, it is\n1930s, Himsworth suggested that there were two phenotypes. The possible that someone with T2DM can move from insulin require-\nfi rst real attempt to classify diabetes came with the fi rst WHO ment to no pharmaceutical intervention through modifi cation of\nExpert Committee on Diabetes Mellitus which felt that the only lifestyle. The main classes are T1DM, T2DM, other specifi c types\nreliable classifi cation was by age of onset and divided diabetes into and gestational diabetes (Table 2.1 ). It should be noted that\njuvenile - onset and maturity - onset disease [2] . There were many T2DM is largely categorization by exclusion.",
    "chunk_id": 168,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 827
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 47
    }
  },
  {
    "text": "As new causes are\nother phenotypes in vogue at that time including brittle, gesta- discovered so they will be included under “ other specifi c types ”\ntional, pancreatic, endocrine, insulin -r esistant and iatrogenic as has occurred for maturity - onset diabetes of the young (MODY). diabetes, but for most cases there was no clear indication of etiol- The classifi cation was revisited by WHO in 2006, but no\nogy. Clarity began to emerge in the 1970s with the discovery of further modifi cation was introduced, and it will be examined\nthe human leukocyte antigen (HLA) genotypes common in juve- again in 2010 when at most minor amendments will be made. nile - onset diabetes and the discovery of islet call antibodies. This IGT was removed from the formal classifi cation of types of dia-\ngave a clear indication that younger patients with diabetes, all of betes – logically, as it is not diabetes – but was retained as a risk\nwhom required insulin therapy, had an autoimmune disorder. state.",
    "chunk_id": 169,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 993
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 47
    }
  },
  {
    "text": "Impaired fasting glycemia (IFG) was introduced as another\nThe beginning of the modern era came with the second WHO risk state. This was particularly important in many countries\nExpert Committee [3] which reviewed and modifi ed the revised where glucose tolerance tests are rarely performed in practice\nclassifi cation published by the National Diabetes Data Group [4] . outside of pregnancy so that IGT was not diagnosed and IFG,\nThis proposed two main classes of diabetes: insulin - dependent although not strictly equivalent, has been used as an easily\ndiabetes mellitus (IDDM; type 1) and non - insulin - dependent obtained risk marker. diabetes (NIDDM; type 2) together with “ o ther types” and ges-\ntational diabetes.",
    "chunk_id": 170,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 722
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 47
    }
  },
  {
    "text": "There were also two risk classes: previous Type 1 d iabetes\nabnormality of glucose intolerance (PrevAGT) and potential T1DM is primarily caused by β - cell destruction although some\nabnormality of glucose tolerance (PotAGT) which replaced previ- insulin resistance is also present (see Chapter 9 ). After the initial\nous types known as pre - diabetes or potential diabetes. stages, insulin is required for survival. In Europids > 90% show\nThe 1980 classifi cation was revised further in 1985 [5] and evidence of autoimmunity with anti - glutamine acid decarboxy-\nreverted to clinical descriptions with retention of IDDM and lase (anti- G AD), anti- i nsulin and/or islet cell antibodies detect-\nNIDDM but omission of type 1 and type 2. Malnutrition - related able. It shows strong association with specifi c alleles at the DQ - A\n25",
    "chunk_id": 171,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 832
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 47
    }
  },
  {
    "text": "--- Page 48 ---\nChapter 2: The Classifi cation and Diagnosis of Diabetes\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nand DQ - B loci of the HLA complex [9] . Not all subjects with the\nTable 2.2 Other specifi c types of diabetes. Adapted from World Health\nclinical characteristics of T1DM show these associations with\nOrganization [6] . autoimmunity although they are ketosis - prone, non - obese and\ngenerally under the age of 30 years. In non - Europid populations, Genetic defects of β - cell function\nup to 80% may show no measurable autoantibodies [10] ; these Chromosome 20, HNF4α (MODY 1)\nare referred to as having idiopathic T1DM. As with autoimmune Chromosome 7, glucokinase (MODY 2)\ndiabetes, however, there is clear loss of β - cell function as meas- Chromosome 12, HNF1α (MODY 3)\nured by low or absent C - peptide secretion.",
    "chunk_id": 172,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 905
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 48
    }
  },
  {
    "text": "Diabetes occurring Chromosome 13, IPF - 1 (MODY 4)\nbefore the age of 6 months is most likely to be monogenic neonatal Mitochondrial DNA 3243 mutation\ndiabetes rather than autoimmune T1DM (see Chapter 15 ) [11] . Others\nIn addition to the typically young people with acute - onset Genetic defects in insulin action\nT1DM, there is an older group with slower onset disease. They Type A insulin resistance\nmay present in middle age with apparent T2DM but have evi- Leprechaunism\ndence of autoimmunity as assessed by GAD antibody measure- Rabson – Mendenhall syndrome\nments and ultimately become insulin - dependent. This is referred Lipoatrophic diabetes\nOthers\nto as latent autoimmune diabetes of adults (LADA) [12] . Disease of the endocrine pancreas\nType 2 di abetes\nFibrocalculous pancreatopathy\nBy far the majority of people with diabetes worldwide have\nPancreatitis (particularly chronic)\nT2DM.",
    "chunk_id": 173,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 896
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 48
    }
  },
  {
    "text": "This is characterized by insulin resistance with relative\nTrauma/pancreatectomy\ninsulin defi ciency (i.e. patients secrete insulin, but not enough to\nNeoplasia\novercome the insulin resistance) (see Chapters 10 and 11 ). Cystic fi brosis\nTypically, they do not require insulin to survive but often will Hemachromatosis\neventually need insulin to maintain reasonable glycemia control, Others\noften after many years. Endocrinopathies\nThe precise molecular mechanisms underlying T2DM are not\nCushing syndrome\nknown. Major efforts have been made to discover underlying Acromegaly\ngenetic abnormalities but with only modest success (see Chapter Pheochromocytoma\n12 ). The most promising to be date has been TCF7L2 [13] which Glucagonoma\nmay have a role in insulin secretion but this does not explain Somatostatinoma\ndiabetes susceptibility in the majority of subjects.",
    "chunk_id": 174,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 862
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 48
    }
  },
  {
    "text": "What is clear is Others\nthat T2DM is closely associated with obesity and physical inactiv-\nDrug - or chemical- induced\nity, and the westernization of lifestyles. The dramatic increase in Nicotinic acid\nT2DM over the past two decades has been closely paralleled by Glucocorticoids\nthe rise in obesity worldwide. Both obesity, particularly visceral Thyroxine/triiodothyronine\nadiposity, and physical inactivity cause insulin resistance which α - Adrenergic agonists\nwill result in diabetes in those with only a small capacity to Thiazides\nincrease insulin secretion. The incidence of T2DM also increases Pentamidine\nVacor\nwith age, which may be related to decrease in exercise and muscle\nOthers\nmass; however, as the incidence increases so T2DM is being\nfound at younger ages and it is now not uncommon in adoles- Infections\ncence in many ethnic groups.",
    "chunk_id": 175,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 851
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 48
    }
  },
  {
    "text": "Congenital rubella\nT2DM occurs in families so that those with a fi rst - degree rela- Cytomegalovirus\ntive with diabetes have an almost 50% life - time risk. There is also Mumps\nOthers\nmarked variation between different ethnic groups. Thus, those of\nPolynesian, Micronesian, South Asian, sub - Saharan African, Uncommon forms of immune- mediated disease\nArabian and Native American origin are much more prone to Insulin autoimmune syndrome\ndevelop diabetes than Europids. Anti - insulin receptor antibodies\nT2DM is a diagnosis by exclusion and the prevalence may fall “ Stiff man ” syndrome\nOthers\nas causes are identifi ed, but this is likely to be a slow process. Other genetic syndromes\nOther sp ecifi c ty pes of d iabetes\n(see Table 2.3 )\nDiabetes occurs both as a result of specifi c genetic defects in\ninsulin secretion and action and in a range of other conditions\n(Table 2.2 ). 26",
    "chunk_id": 176,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 889
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 48
    }
  },
  {
    "text": "--- Page 49 ---\nChapter 2: The Classifi cation and Diagnosis of Diabetes\nPart 1: Part 1 Diabetes in its Historical and Social Context\nClassifi cation and Diagnosis of Diabetes Mellitus Chapter 2\nThe best known of the defects in insulin secretion are the diagnostic criteria). There is signifi cant morbidity associated with\nMODY family, which are a group of autosomal - dominant inher- GDM including intrauterine fetal death, congenital malforma-\nited disorders where there is hyperglycemia at an early age, gener- tions, neonatal hypoglycemia, jaundice, prematurity and macro-\nally of a mild nature. The most common concerns a mutation in somia. Risk factors for GDM include certain ethnic groups, those\nthe HNF - 1 α gene on chromosome 12 (MODY 3) while another with previous GDM or abnormalities of glucose tolerance, age,\nis caused by mutations in the glucokinase gene on chromosome obesity and previous large babies. 7p.",
    "chunk_id": 177,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 925
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 49
    }
  },
  {
    "text": "These account for a small number of people with diabetes but\nare important in determining therapeutic approaches. Risk s tates\nThe association of diabetes with defects in insulin action has Prior to the 1979 and 1980 reports, the state of “ borderline ”\nlong been known, particularly in type A insulin resistance, lepre- diabetes had been recognized for cases where there was uncer-\nchaunism and lipoatrophic diabetes. Not surprisingly, diseases of tainty about the diagnosis of diabetes but where plasma glucose\nthe exocrine pancreas often cause diabetes through destruction was above accepted normal levels. This was formalized by the\nof the islets. Pancreatitis secondary to alcohol is probably the NDDG and WHO [3,4] as IGT, a higher than normal plasma\nmost common of these (see Chapter 18 ). Hemochromatosis and\ncystic fi brosis also commonly result in diabetes. Fibrocalculous pancreatitis is also included in this category. Table 2.3 Other genetic syndromes associated with diabetes.",
    "chunk_id": 178,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 990
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 49
    }
  },
  {
    "text": "Adapted from\nOriginally, this was part of malnutrition - related diabetes mellitus World Health Organization [6] . where there were two proposed variants: one associated with\ncassava consumption in malnourished people but without Down syndrome\nevidence of calculi, while the other was found after tropical Friedreich ataxia\npancreatitis and presented with fi brocalculous disease. The latter Huntington chorea\nKlinefelter syndrome\nis akin to the diabetes found with other forms of chronic pan-\nLawrence – Moon – Biedl syndrome\ncreatitis. In 1999 it was felt that this latter form would fi t into\nMyotonic dystrophy\nthe category of “ other specifi c types ” and that more evidence\nPorphyria\nwas needed before a specifi c malnutrition - related diabetes cate-\nPrader – Willi syndrome\ngory could be included. Turner syndrome\nSeveral endocrinopathies are associated with diabetes: Cushing Wolfram syndrome\nsyndrome, acromegaly, pheochromocytoma, glucagonoma and Others\nhyperthyroidism (see Chapter 17 ).",
    "chunk_id": 179,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 999
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 49
    }
  },
  {
    "text": "In general, the diabetes will\ndisappear if the endocrinopathy is treated. Many drugs and\nchemicals cause diabetes (Table 2.2 , Chapter 16). Some of these\ncause β - cell destruction but others will cause diabetes by increas-\nTable 2.4 World Health Organization (WHO) recommended criteria for the\ning insulin resistance in susceptible individuals. diagnosis of diabetes and intermediate hyperglycemia. Infections are also associated with the development of diabetes;\nclassically, mumps, congenital rubella, coxsackie B and cytome- Diabetes\ngalovirus are the main ones implicated. Many genetic syndromes Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL)\nare also associated with diabetes (Table 2 .4) . and/or\nThere are other types of diabetes that do not fi t conveniently 2 - hour post - glucose load ≥ 11.1 mmol/L (200 mg/dL)\ninto any of the current classes.",
    "chunk_id": 180,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 856
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 49
    }
  },
  {
    "text": "These include “ Flatbush ” diabetes plasma glucose\nfound in Afro - Americans [14] and so - called ketosis - prone T2DM Impaired glucose tolerance\nfound in Africans in sub - Saharan Africa [15] . These are both Fasting plasma glucose < 7.0 mmol/L (126 mg/dL)\ncharacterized by periods of ketosis with absolute insulin depend- and\nence and other times when the diabetes can be controlled by diet 2 - hour post - glucose load\nalone. plasma glucose ≥ 7.8 and < 11.1 mmol/L (140 and 200 mg/dL)\nImpaired fasting glycemia\nGestational d iabetes m ellitus Fasting plasma glucose 6.1 – 6.9 mmol/L (110 – 125 mg/dL)\nGestational diabetes mellitus (GDM) is hyperglycemia fi rst and (if measured)\ndetected during pregnancy (see Chapter 5 3) . This is distinct from 2 - hour post - glucose load < 7.8 mmol/L (140 mg/dL)\nwomen with diabetes undergoing pregnancy, who have diabetes plasma glucose\nin pregnancy rather than gestational diabetes. Plasma glucose\nNB. All values refer to venous plasma glucose.",
    "chunk_id": 181,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 987
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 49
    }
  },
  {
    "text": "Capillary plasma glucose\nlevels, both fasting and post - prandial, are lower than normal in\nvalues would be the same fasting but 1 mmol/L (18 mg/dL) higher than\nearly pregnancy so that raised levels at this stage are almost cer-\nvenous levels after the glucose load. The glucose load is 75 g anhydrous\ntainly caused by previously undetected T2DM. Screening for\nglucose. GDM is generally undertaken at around 28 weeks (see below for\n27",
    "chunk_id": 182,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 434
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 49
    }
  },
  {
    "text": "--- Page 50 ---\nChapter 2: The Classifi cation and Diagnosis of Diabetes\nPart 1: Part 1 Diabetes in its Historical and Social Context\nPart 1 Diabetes in its Historical and Social Context\nglucose 2 hours after a glucose load but below the diagnostic indicated the probability of diabetes. This was for whole blood so\ncutoff for diabetes. Later, both the ADA and WHO introduced that in terms of plasma this would equate to about 150 mg/dL\nthe concept of IFG as a fasting plasma glucose above normal but (8.3 mmol/L); however, at that time, most blood glucose\nbelow the diabetes diagnostic level [ 6,7]. Both IFG and IGT are chemical tests in use overestimated true glucose by at least\nassociated with a two - to threefold increased risk of developing 20 mg/dL (1.1 mmol/L). They placed most reliance on the OGTT. diabetes, while IGT is also a cardiovascular risk marker.",
    "chunk_id": 183,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 868
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  },
  {
    "text": "IFG was They examined both values at 1 and at 2 hours after the glucose\nwelcomed as it could indicate an at - risk individual without the load but decided that the 2 - hour value on its own was adequate\nneed to perform a glucose tolerance test. Collectively, IFG and – and this was the key diagnostic test suggested. The value\nIGT became known as “ pre - diabetes ” – a misleading term as not selected was 130 mg/dL (7.2 mmol/L) for venous whole blood\neveryone with pre - diabetes develops diabetes, and it diminishes and that was to be applied regardless of whether the 50 - g or the\nthe importance of other risk markers such as family history. The 100 - g glucose load was given. They also introduced the important\nterm “ intermediate hyperglycemia ” is preferred by WHO [16] .",
    "chunk_id": 184,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 779
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  },
  {
    "text": "concept of “ borderline ” diabetes – the forerunner of IGT – where\nIGT and IFG are more likely in older people, those who are obese, values were to be above normal but less than those diagnostic for\npeople from particular high risk ethnic groups and those with diabetes: 110 mg/dL (6.1 mmol/L) to 129 mg/dL (7.2 mmol/L) for\ncardiovascular disease or other features of the metabolic syn- venous whole blood 2 hours after the glucose load. drome, such as dyslipidemia, hypertension or visceral adiposity. O ne further important comment is the need for people to be\nprepared for the OGTT with at least 250 g carbohydrate con-\nsumed for 3 days before the test. This still applies and is rarely\nDiagnostic c riteria adhered to, which may explain the large number of older people\nwith normal fasting glucose but elevated 2 - hour values. Many of\nThe diagnosis of diabetes mellitus has lifelong implications for these could well have “ starvation ” diabetes rather than genuine\nthe individual.",
    "chunk_id": 185,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 986
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  },
  {
    "text": "Thus, both the clinician, and person tested, must diabetes. have full confi dence in the diagnosis. In the symptomatic indi-\nvidual this is easier but in asymptomatic people once an abnor- The m odern e ra\nmal test has been found it must be confi rmed by a further test. The big change and rationalization came in 1979 and 1980 with\nThis is increasingly important as screening programs spread and the work of NDDG and WHO [3,4] . They reviewed all available\nalso because 30 – 50% of people with T2DM are asymptomatic data and concluded that a 75 - g load would be appropriate and\nand unaware that they have the disorder. that this should be consumed in 300 mL water over 5 minutes.",
    "chunk_id": 186,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 681
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  },
  {
    "text": "They based the diagnostic levels for fasting and 2 - hour values\nClinical d iagnosis of d iabetes in largely on bimodality observations in high prevalence groups\ns ymptomatic i ndividuals such as the Pima Indians and on some observations of risk for\nThe search for diabetes in an individual is often driven by the retinopathy. Fasting and 2 - hour venous plasma levels of 140 mg/\npresence of characteristic symptoms such as thirst, polyuria, dL (7.8 mmol/L) and 200 mg/dL (11.1 mmol/L) were recom-\nweight loss, recurrent infections and, in more severe cases, pre - mended by NDDG and these were – somewhat unfortunately –\ncoma. In such individuals, a single elevated casual plasma glucose rounded up to 8 mmol/L and 11 mmol/L by the WHO Committee. value is suffi cient to confi rm the diagnosis. A defi nite diagnosis IGT was defi ned as a fasting venous plasma value < 8 mmol/L with\ncan be assumed if the venous plasma glucose level is greater than a 2 - hour value of 8 – 11 mmol/L.",
    "chunk_id": 187,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 984
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  },
  {
    "text": "Confusion was rife and a further\n11.1 mmol/L (200 mg/dL) or 12.2 mmol/L (220 mg/dL) in capil- evaluation took place in 1985 [5] when the WHO group adjusted\nlary plasma [5] . WHO describes values of 5.0 – 11.0 mmol/L as their values to match the NDDG values precisely. uncertain. Further testing is then required as described below. The next big change occurred in 1997 and 1999 with the pub-\nlication of the ADA and the new WHO report. This time a con-\nDiagnostic t e sts for d iabetes siderable amount of data were available to look at risk of\nA raised blood glucose has been the hallmark of diabetes mellitus retinopathy at different glucose levels. The data were cross -\nfor over 100 years.",
    "chunk_id": 188,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 693
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  },
  {
    "text": "The oral glucose tolerance test (OGTT) was sectional but reasonable agreement was shown between studies\ndeveloped in the early years of the 19th century but only came of Egyptians, US citizens from NHANES III and Pima Indians\ninto common use as methods for measuring blood glucose (for review see Expert Committee on the Diagnosis and\nbecame easier. When the fi rst WHO Expert Committee on Classifi cation of Diabetes Mellitus [7] ). Although there was some\nDiabetes reviewed diagnostic tests [2] they fi rst of all stated that tolerance on the precise values, the existing 2 - hour cut point of\nglycosuria was an unsatisfactory test and that neither the presence 11.1 mmol/L (200 mg/dL) seemed reasonable but the fasting\nof glycosuria nor its absence could rule in or rule out diabetes. value was lowered to 7.0 mmol/L (126 mg/dL; Table 2.4 ). At the\nThey also commented on the wide range of glucose tolerance tests same time, the concept of IFG was introduced.",
    "chunk_id": 189,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 962
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  },
  {
    "text": "This was equiva-\navailable at the time and recommended strongly that only the lent to IGT but for the fasting state and was meant to indicate a\n50 - g or the 100 - g OGTT should be used. They suggested that a risk state for diabetes. The values chosen were 6.1 – 6.9 mmol/L\nfasting venous blood glucose level over 130 mg/dL (7.2 mmol/L) (110 – 125 mg/dL). 28",
    "chunk_id": 190,
    "metadata": {
      "type": "paragraph_chunk",
      "chunk_size": 358
    },
    "document_metadata": {
      "part": "Part 1",
      "part_title": "Part 1 Diabetes in its Historical and Social Context",
      "chapter": 2,
      "chapter_title": "The Classifi cation and Diagnosis of Diabetes",
      "page_number": 50
    }
  }
]